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Parkinson’s Disease (PD) is one of the most common neurodegenerative diseases in the world. Despite its 
prevalence, the disease is difficult to diagnose early with the vast majority of individuals already having 
significant neuronal death prior to therapeutic intervention. PD is characterized by the lysosome’s unusual 
inability to dispose of α-synuclein in areas of the brain that primarily control motor function. Recently, 
studies have shown that in post-mortem brain samples from suspected PD patients, there is a deficiency in 
the activity of the lysosomal enzyme glucocerebrosidase (GCase). GCase is a retaining β -glucosidase that 
hydrolyzes glucosylceramide in the lysosomes of normal cells. Interestingly, deficiency in enzyme 
activity was found in both early or late stages of the disease suggesting that GCase could be a biomarker 
of early PD. To validate GCase as a potential biomarker this thesis focuses on the development of 
molecular probes for the detection of GCase activity in biological systems. Recently the Phenix lab has 
developed a class of N-alkylated conduritol aziridines that were shown to be potent and selective 
irreversible inhibitors of GCase in vitro. A new synthesis pathway has been developed to synthesize these 
compounds more efficiently and which can be adaptable for producing fluorescent derivatives for in vitro 
imaging and radioactive derivatives for in vivo imaging. Two new fluorescent derivatives have been 
developed as well two fluorinated derivatives for future radiolabelling. The development of techniques to 
radiolabel these compounds is shown in this work. Future work will be done to optimize radiolabelling 
and test these molecular probes for imaging GCase in biologically relevant systems to validate it as a 
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 Glucocerebrosidase (GCase) is a lysosomal enzyme that catalyzes the hydrolysis of the β-
glucosyl linkage in the natural substrate glucosylceramide (Figure 1). GCase is classified as a retaining β-
glucosidase meaning it has specificity for cleaving β-glucosyl linkages and the β configuration of the 
resulting glucose is retained after cleavage.1  
 
Figure 1: The hydrolysis of glucosylceramide by lysosomal retaining β-glucosidase GCase.  The hydrolysis is 
catalyzed by glutamic acid residues 235 and 340. A complex with co-enzyme Saposin C is required for catalysis. 
The mechanism of action for substrate hydrolysis by GCase has been elucidated through the study 
of X-ray crystal structures and studies done with irreversible active site inhibitors.2 Studies have shown 
that the active site of GCase contains two catalytic glutamic acid residues, Glu235
 and Glu340,
 which are 
involved in a two-step double displacement mechanism for the hydrolysis of glucosylceramide (Figure 2). 
In the first step of the mechanism, upon substrate binding with the enzyme’s active site, Glu340
 performs a 
nucleophilic attack on the anomeric carbon in glucosylceramide. This nucleophilic substitution reaction is 
catalyzed by Glu235 acting as a general acid protonating the displaced ceramide. This SN2 reaction has 
been shown to proceed through an oxycarbenium ion-like transition state stabilized through hydrogen 
bonding and various electrostatic interactions with active site residues.3 The first step results in cleavage 
of the β-glycosidic bond in glucosylceramide, release of ceramide and the formation of a covalent 
glucosyl-enzyme intermediate. In the last step, which also proceeds through a oxocarbenium-ion like 
transition state, the glucosyl-enzyme intermediate is hydroyzled to release β-glucose whilst regenerating 





Figure 2: The catalytic mechanism of glucosylceramide hydrolysis by GCase.  Glutamic acid residue 340 
performs a nucleophilic attack on the β-glyosidic linkage. This reaction is catalyzed by Glutamic acid residue 235, 
forming a oxocarbenium ion like transition state which collapses to give a covalent glucosyl-enzyme intermediate. 
This intermediate is converted back to its starting configuration upon hydrolysis  to yield β-glucose.  
Evidence of the existence of a glucosyl-enzyme intermediate in the double displacement 
mechanism comes from X-ray cyrstallography and spectrocopic studies using active site inhibitors such 
as 2-deoxy-2-fluoro-D-glucosyl fluorides2 or conduritol-B-epoxide (CBE)4 through trapping of the 
covalent inhibitor-enzyme intermediate. An X-ray crystal structure showed CBE to be covalently bound 
to Glu340 of GCase and can be seen later in this thesis in Figure 7B.  
GCase is expressed from the GBA1 gene and is translated in the cytosol of the cell.5 GCase is a 
lysosomal enzyme so for proper function it must be relocated. After translation the protein is recognized 
by trafficking receptor LIMP2 and packaged in a vesicle.6 This is all facilitated in the endoplasmic 
reticulum. GCase is trafficked from the endoplasmic reticulum to the Golgi for further processing and will 
finally reach the lysosome where the vesicle empties its cargo7 (Figure 3). Once GCase reaches the 
lysosome it forms a complex with co-activator Saposin C and hydrolyzes its substrate glucosylceramide 
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on the surface of the lysosomal membrane. The exact mechanism by which this complex forms remains 
controversial but it is known that Saposin C is required for GCase enzymatic function8. 
Glucosylceramide hydrolysis is important in the production of ceramide for cells. Ceramide is a 
required precursor for many lipid metabolic pathways and its production has a large impact on cellular 
membrane structure as well as many signalling pathways.9 Ceramide can alternatively be generated 
through de novo synthesis and through the breakdown of sphingomyelin but in some cells10, like neurons, 
glucosylceramide hydrolysis accounts for 50-90% of sphingolipid production.11 Deficiencies in GCase 
can therefore have a large impact in cellular ceramide levels. Deficiencies in GCase can also result in 
harmful accumulation of glucosylceramide in the lysosome as seen in Figure 3. Severe GCase enzyme 
deficiency, which can occur from the inheritance of mutated GBA1 genes, will result in a lysosomal 
storage disorder known as Gaucher Disease. Interestingly, mutation of the GBA1 gene and Gaucher 







Figure 3: Upon expression of GCase from the GBA1 gene, GCase is packaged up into a vesicle for transport 
to the Golgi. This transport is mediated by transport receptor LIMP-2. In the Golgi GCase is processed so that it 
may be suitable to function once it gets to the lysosome. In the lysosome GCase forms complexes with Saposin C on 
the lysosomal membrane and glucosylceramide is hydrolyzed. In the case where a mutated GBA1 gen e expresses 
improperly folded enzyme the mutant GCase becomes ubiquitinated and targeted for protein degradation. This 
deficiency in lysosomal GCase activity results in a build up of glucosylceramide that eventually will cause 
symptoms associated with Gaucher Disease.  
Gaucher Disease: a Lysosomal Storage Disorder 
 The lysosome is a single membraned organelle found in most eukaryotic cells.12 It is known as 
the digestive or recycling organelle because of its enzymatic contents. These can include acid 
phosphatases ribonucleases, deoxyribonucleases, cathepsins, glycosidases and sulfatases.12 Deficiencies 
in any of these enzymes can result in lysosome dysfunction causing disruptions in natural metabolic 
pathways, destruction of some signalling pathways or lysosomal membrane leakage causing intracellular 
damage.9 Depending on which enzyme, many different diseases can arise from enzyme deficiency (Figure 




Figure 4: Common lysosomal storage diseases and the enzymes involved in their pathogenicity.  A deficiency in 
GCase results in Gaucher Disease.14  
 The most common lysosomal storage disease is Gaucher Disease where 1 in 40,000-50,000 live 
births will be born with the disease.15 The Ashkenazi Jews are an ethnic group with the highest risk of 
developing Gaucher Disease with 1 in 800 people inheriting the disease.16 The disease is a recessive 
genetic disorder where a number of mutations in the GBA1 gene can cause a dysfunctional GCase 
enzyme to be expressed.17 In these cases, the mutant enzyme does not fold properly preventing trafficking 
across the endoplasmic reticulum or the mutation disrupts its ability to interact with Saposin C. 18 As can 
be inferred from Figure 4, lysosomal GCase deficiency will result in lysosome dysfunction after 
accumulation of glucosylceramide begins. Significant reduction in ceramide production results and in turn 
reduction in sphingolipid synthesis will occur having severe pathological implications.14 
 In Type I Gaucher Disease, the main symptoms are chronic pain resulting from inflammation and 
enlargement of the spleen and liver (splenomegaly, hepatomegaly), blood related problems (anaemia, 
thrombocytopenia) and chronic bone pain (osteopenia, osteonecrosis and skeletal deformities)19 resulting 
from deficient GCase activity primarily in macrophages.14 These symptoms, with the addition of severe 
neurological symptoms effect patients with Type II (acute neurological) and Type III (chronic 
neurological) Gaucher Disease, both of which are deadly forms.20  
 Currently the most effective form of therapy for Gaucher Disease is through Enzyme 
Replacement Therapy. This involves injections of exogenously produced enzyme to increase otherwise 






Genzyme under the market name of Cerezyme®. Enzyme Replacement Therapy with Cerezyme® is an 
extremely expensive option so research has recently focused on the discovery of small molecular 
chaperones that can help traffic mutated GCase to the lysosome through binding to the active site 
stabilizing the folded tertiary structure and thus escaping ubiquination and degradation in the ER.22 
Discovery of such molecular chaperones for GCase has gained increased importance due to new evidence 
suggesting the heavy involvement of GCase in the progression of Parkinson’s Disease as described 
below.  
GCase as a Potential Biomarker of Parkinson’s Disease 
 Parkinson’s Disease (PD) is one of the most common neurodegenerative diseases in the world.23 
Its symptoms are clinically characterised by bradykinesia (slowness of movement), resting tremor, 
postural instability and eventually, cognitive impairment such as dementia.24 The underlying pathology in 
PD involves the abnormal accumulation of α-synuclein protein fibrils. Normally α-synuclein is highly 
soluble in the cell but in PD this protein forms highly ordered insoluble aggregates in the neurons of the 
brain.25 Large aggregates, otherwise known as Lewy Bodies, form in the lysosomes of dopaminergic 
neurons.24 The eventual result of Lewy Body growth is the death of dopaminergic neurons in the brain.26 
Dopaminergic neurons are those involved in the transmission of dopamine throughout the brain, an 
important neurotransmitter required for normal brain function.27 In PD, Lewy Body formation occurs 
primarily within neurons of the substantia nigra region of the brain, a region responsible for the motor 
impairment symptoms that are classic to PD. As PD progresses to advanced stages of the disease, Lewy 
Body formation can spread to neocortical regions of the brain, as it does with 80% of patients, producing 
severe cognitive impairments such as Lewy Body dementia.28  
 PD is a disease without a cure. The most effective treatment for PD to date is treatment through 
dopamine replacement therapy. This therapy includes the replacement of dopamine by the administration 
of levodopa, dopamine agonists or by using monoamine oxidase B inhibitors.29 Artificial dopamine 
replacement helps alleviate the loss of dopamine caused by the death of dopaminergic neurons. 
Unfortunately, this does not slow the progression of the disease but only helps patients manage PD 
symptoms related to the loss of dopaminergic neurons.30 However, sometimes patients feel that the side 
effects from these therapies can be worse than the disease itself.30 Since it is often worse to receive 
unnecessary dopamine replacement therapy rather than begin therapy early, clinical diagnosis of PD takes 
around two years before treatment begins.31 This results in a large use of healthcare resources and can be 
very stressful for the patient. Not to mention the patient has to go this entire time without treatment. 
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 Clinical diagnosis of PD relies on the presence of the motor impairment symptoms described 
above and the absence of other features indicative of similar neurodegenerative disorders.24 When clear 
signs of these symptoms are present it is estimated that the accuracy of a clinical diagnosis is 76 to 92%. 32 
The issue is, as stated in most reviews, motor symptoms only present themselves after 50% of 
dopaminergic neurons in the substantia nigra are already dead.33 It is early diagnosis which is difficult 
because early clinical symptoms overlap with other diseases like multiple system atrophy, corticobasal 
degeneration and progressive supranuclear palsy.24 These diseases all share common physical symptoms 
and mainly differ in their pathophysiology. Currently, no blood test or imaging agent exists for the 
biochemical diagnosis of PD or the detection of Lewy Bodies in vivo.24 Indeed, neuronal Lewy Body 
formation can only be confirmed during post-mortem brain tissue examination.34  
Since Lewy Body pathophysiology is a very early indicator of PD, detection of α-synuclein levels 
in the brain could potentially accurately diagnose early PD compared to clinical diagnosis through expert 
symptom assessment. Efforts have been made to image α-synuclein using Positron Emission Tomography 
(PET) but the inability to develop imaging probes that specifically bind to α-synuclein over other 
neuronal fibrils has been a major set-back in probe development.24 Imaging dopamine uptake is the only 
current imaging method used to gather biochemical information about PD. Through the use of DaTscan® 
clinicians are able to visualize uptake of a radioactively labelled dopamine to gather molecular 
information about the disease characterized by the loss of dopaminergic neurons.35 The problem with this 
technique is the loss of dopaminergic neurons is not specific to PD so DaTscans can only help confirm a 
diagnosis not make one by themselves. Neurologists currently have to use a “wait and watch” philosophy 
when it comes to accurately diagnosing and treating PD.29 Surely waiting for a disease to progress until 
severe symptoms appear is not an ideal strategy for disease management. The early stages of PD may 
provide the most opportune time for intervention although it remains the most difficult time to diagnosis. 
By having a tool to detect early Lewy Body formation, through either direct or indirect detection, 
neurologists may be able to extend the quality of life of their patients by influencing what therapies a 
patient receives and when they receive them while researchers may be equipped with a better tool for 
developing a cure.  
 Interestingly, GCase may be an effective target for developing such a tool. Recently, studies have 
shown that patients with Gaucher Disease are at a higher risk of developing PD compared to a healthy 
control. One study of nearly 6000 patients showed that Type I Gaucher Disease patients are 6 to 17 fold 
more likely to develop PD compared to a healthy group of patients.36 Although Gaucher Disease patients 
have homozygous mutations of the GBA1 gene, other studies have shown that that even heterozygous 
carriers of GBA1 mutations are at higher risk than the general population. A study of large cohorts of PD 
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patients showed 4-7% were found to carry heterozygous GBA1 mutations.37 A different study looking at 
57 post-mortem brain samples from PD patients demonstrated 12% carried at least one mutation in the 
GBA1 gene which is a higher GBA1 mutation frequency than within the at risk Ashkenazi Jewish 
population.38 One of the most surprising discoveries was that in a group of 5000 patients it had been 
demonstrated that there was a greater than 1 in 5 chance for a PD patient to carry a GBA1 mutation thus 
making genetic defects in the GBA1 gene the most significant genetic risk factor for PD identified to 
date.39  
It is clear that there is a strong correlation between GBA1 mutations and the occurrence of PD but 
further investigation in cells, animals and humans was required to understand the role that GCase has in 
the progression of the disease. The most obvious trend to investigate was the correlation between GCase 
and Lewy Body formation. A dementia study has shown that of 95 patients with pathological Lewy Body 
findings, 28% of them had GBA1 mutations.40 When another group examined post-mortem brain samples 
from PD patients, they found that from the patients that were homozygous and heterozygous for GBA1 
mutations, 80% and 75% respectively showed that the GCase protein was co-localized within the Lewy 
Bodies.39 In fact it was demonstrated that in cell lines with a GBA1 deficiency, global lysosomal 
dysfunction was correlated with α-synuclein aggregation.41 This suggests that the expression of mutant 
GCase can lead to increased formation of Lewy Bodies. 
 Increased α-synuclein levels were not only shown to occur in cell lines with GBA1 knockouts but 
also in vivo with GBA1 mutant mouse models of Gaucher Disease. It has been shown over the course of 
the mouse’s life, increases in α-synuclein levels were directly correlated to decreases in GCase enzymatic 
activity.13 Interestingly, mice receiving injections of exogenous recombinant GCase enzyme were found 
to have reduced levels of α-synuclein, fewer pathological Lewy Bodies and ameliorated cognitive 
symptoms associated with PD.13 This data  is consistent with results obtained from experiments using cell 
lines having GBA1 deficiency and lysosomal dysfunction that promoted α-synuclein aggregation but 
recovered normal lysosomal function with the addition of exogenous GCase.41 This suggests that GCase 
activity alone is able to mitigate the aggregation of α-synuclein in the formation of Lewy Bodies 
presumably due to normal lysosomal function.  
 The most perplexing data reported in the literature is that of observable decreases in GCase 
activity in PD patients without any GBA1 mutations. This was perplexing because it was initially thought 
that the decrease in GCase activity in PD patients was directly a consequence of mutant enzyme that was 
unable to reach the lysosome. One thorough investigation evaluated 19 post-mortem brain samples from 
patients confirmed of having PD but no GBA1 mutations.42 The patients varied from being afflicted by 
early to late stages of progression of PD. Neuronal death was only present in the late stage samples, 
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although, sodium dodecyl sulphate (SDS) soluble α-synuclein levels were elevated in all samples. SDS-
soluble refers to proteins that are largely insoluble in water but will only dissolve in the presence of strong 
detergents like SDS. This includes samples containing insoluble α-synuclein aggregates (Lewy Body) or 
GCase. There was a strong negative correlation shown between the levels of SDS-soluble α-synuclein 
increasing and the SDS-soluble GCase levels decreasing. Lysosomal GCase enzyme activity was also 
shown to decrease. This observation was seen in both early and late stages of the disease. This is 
interesting because GCase activity is shown to decrease even in early stages of the disease before 
neuronal death has occurred. Furthermore, these results were taken from patients without GBA1 
mutations who expressed the wild type enzyme suggesting that GCase activity may decrease in all 
patients with PD. These two facts together highlight the significant impact GCase may have as a 
biomarker for the progression of PD or a therapeutic target. Indeed, lysosomal activity and cellular levels 
of GCase are shown to be decreased early on in the disease, before neuronal death has occurred and in 
patients without any GBA1 mutations suggesting that GCase activity may be a universal biomarker for 
PD patients. 
It is also interesting to note that there were reductions in GCase concentration, both in the 
cytoplasm and lysosome, in the early stages of the disease. Despite this early reduction, GCase 
concentration in the cytoplasm seemed to remain at this level, even in the late stage PD samples.42 GCase 
mRNA levels also appeared to remain constant throughout the progression of the disease. Lysosomal 
GCase enzymatic activity, however, seemed to drop continuously as the disease progressed from early to 
late.42 (This information is summarized in Table 1). This suggests that in PD there is not a reduction in the 
GCase being produced but rather the amount that is reaching the lysosome. A separate study has 
demonstrated that there is some kind of bidirectional pathogenic loop in PD where α-synuclein 
accumulation reduces GCase trafficking to the lysosome while trafficking of GCase to lysosome reduces 
α-synuclein levels (Figure 5).43 This suggests GCase also presents a therapeutic target through promotion 
of its trafficking to the lysosome as it may reduce α-synuclein aggregation. 
Table 1: Summarization of GCase and α -synuclein level analysis in post-mortem human neurons affected by 
PD. The + symbols represent an arbitrary increase or decrease and are not set to any scale but are used to 





GCase Levels Neuronal 
death Cytoplasm Lysosome 
Healthy +++  +++ +++ No 
Early PD +++ + ++ ++ No 
Late PD +++ +++ ++ + Yes 
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 In conclusion, this evidence demonstrates GCase activity levels are directly correlated with the 
accumulation of α-synuclein, the formation of Lewy Bodies and thus the pathogenicity of PD. The disease 
is promoted by the inheritance of mutant forms of GCase but can still progress regardless of the existence 
of GBA1 mutations. The exact reason GCase activity levels drop in PD patients is still unknown and is 
thought to be part of some negative feedback loop between α-synuclein aggregation and GCase 
trafficking to the lysosome. More importantly it has been shown that lysosomal GCase activity decreases 
occur early on in the progression of PD and can be detected before neuronal death occurs. These data 
conclude that GCase is an attractive potential biomarker for detecting the early and accurate onset of PD 
and as a potential therapeutic target for drug development in patients with or without GBA1 mutations. 
Further studies are required to test these assumptions through the design of molecular tools that are able 
to track and measure GCase activity in vitro and in vivo. 
 
Figure 5: GCase is thought to be important in the degradation of α-synuclein in the lysosome.  When GCase 
levels in a functioning lysosome are high, α-synuclein aggregation is not seen. In the case of PD GCase levels in the 
lysosome appear to be low and α-synuclein levels increase until large aggregates form in the lysosome (Lewy 
Body). It is thought when α-synuclein levels are high they somehow have a negative impact on GCase trafficking to 
the lysosome, increasing further their aggregation. Mutant GCase is also unable to travel to the lyso some making 
GBA1 mutations strong risk factors for developing Lewy Body formation .7  
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GCase Molecular Probe Design  
 To validate GCase as a biomarker for PD molecular tools need to be developed to study its 
activity in vitro and in vivo. Since activity of GCase is shown to be decreased in patients with PD it is 
desirable to develop activity-based probes in order to detect activity and track GCase biodistribution 
within a biological system. 
Activity-based protein profiling enlists the help of a small molecule that is designed to interact 
with the active site of a particular enzyme. These activity-based probes take advantage of an enzyme’s 
catalytic mechanism in order to irreversibly bind within the active site.44 Probes can be developed by 
taking a compound that binds well to the active site of an enzyme and coupling to this compound a 
detectable tag such as a fluorescent molecule or a radioactive isotope. Typically, these probes must have 3 
characteristics in order for them to be excellent activity based probes; 1) high affinity for the active site so 
they can bind to the enzyme at biologically significant concentrations, 2) high selectivity to the target 
enzyme so they produce a signal for only one target, 3) a “warhead” that does not reduce active site 
binding and forms an irreversible covalent bond at some point during the enzyme’s catalytic 
mechanism.45 Two off-site targets to be concerned with for the production of GCase activity based probes 
are GBA2 and GBA3 which are β-glucosidases from the same family as GCase. These glucosidases are 
found in the cytosol rather than the lysosome.46 Often compounds that are potent binders of GCase also 
bind well with GBA2 or GBA3. To design an activity-based probe that is specific for GCase it is 
necessary to consider what compounds have already been shown to be potent and selective inhibitors of 
the enzyme.  
One of the first and obvious structures to mimic for an activity based probe is GCase’s natural 
substrate glucosylceramide. The structure of the natural substrate of an enzyme is often used as a starting 
point in the design of inhibitors but glucosylceramide is not simple to synthesize in large amounts or 
simple to chemically modify. One way of circumventing this issue is by replacing the ceramide moiety 
with a different leaving group while keeping the glucose moiety intact considering glucose’s natural 















Figure 6: 2-deoxy-2-fluoroglucoside as mechanism based inhibitors of GCase.  A) By replacing the 2 position on 
glucose with electron withdrawing fluorine it is possible to deactivate the transition state during glycosylation so 
that its deglycosylation has a half life of greater than 1300 min. B) Table shows the IC50 values associated with 
different 2-deoxy-2-fluoroglucoside leaving groups. 
Interestingly, Withers et al. has shown that if you replace one of the hydroxyls on glucose with an 
electronegative fluorine and install a good leaving group at the anomeric carbon, this generates a 
mechanism-based inhibitor where the glucosyl-enzyme intermediate is rapidly formed but only slowly 
hydrolyzed, especially when the fluorine is in the 2 position (Figure 6A).47 There are several examples of 
this type of activity-based probe with fluorine in the 2 position and a good leaving group on the anomeric 
oxygen of glucose (Figure 6B).44 For example, Phenix et al. synthesized a β-2,4-Dinitrophenyl-
fluorodeoxyglucose 1.1 (Figure 8) for the purpose of labelling Cerezyme®, a recombinant form of GCase 
used for treating Gaucher Disease.48 They successfully synthesized the compound with radioactive 
fluorine-18 (18F) showing the glucosyl-enzyme is extremely stable (t½ > 1300 min). Despite a very stable 
glucosyl-enzyme intermediate, as can be seen from IC50 values in Figure 6B, these 2-fluoroglucose probes 
suffer from terrible binding affinities that are probably attributed to the loss of a crucial hydroxyl group 
required for binding and deactivation of the probe as a whole by fluorine making it less reactive for the 





             
Figure 7: Inactivation of mechanism based inhibitor conduritol-B-epoxide (CBE). A) Proposed mechanism of 
GCase inactivation. B) Crystal structure of CBE covalently bound to GCase (PDB: 1Y7V)4 shows extensive 
hydrogen bonding and a covalent bond between CBE and glutamic acid 340.  
 One of the first and most widely available irreversible inhibitors of GCase is conduritol-B-
epoxide (CBE) 1.2 having a Ki value of ~140 μM.49 Unlike the fluorosugar inhibitors that are 
pyranohexoses, CBE is an inositol based compound whose polyhydroxyl cyclohexane conformation 
demonstrates excellent GCase active site recognition. Unlike glucose of the natural substrate, CBE is not 
an pyranose and as a result cannot be efficiently hydrolyzed from the active site of the covalent inhibitor-
enzyme complex. The covalent complex has been shown to form through nucleophilic attack from 
glutamic acid residue 340 on the epoxide of CBE (Figure 7A). In 2005 Premkumar et al. published a 
crystal structure of CBE covalently bound to GCase (Figure 7B) proving that the hydroxyl groups of the 
conduritol backbone formed hydrogen bonds within the active site and that the epoxide did indeed open to 
form a covalent bond with the nucleophilic glutamic acid 340.4  
 CBE is a relatively poor inhibitor of GCase but it exhibits preferential binding of GCase over 
GBA2 and GBA3.4 In addition, this inhibitor is a poor scaffold to build upon and explore new derivatives 
of this type of inhibitor because it lacks any obvious handles to install a radiolabel or fluorescent reporter 








Figure 8:  Structures of selected mechanism based inhibitors of GCase.  
 
Table 2:  Summarized kinetic data on compounds 1.1 to 7 for inhibition of GCase.  
Compound IC50 (μM) Ki (μM) ki (min
-1) ki/Ki (μM
-1/min-1) Reference 
1.1 >1000 - - 12.00 48 
1.2 9.49 140 0.590 4.20 x 10-4 49 
1.3  0.152 0.078 0.514 50 
1.5 0.00194 0.008 0.208 25.10 50 
1.6 0.00115 - - - 53 
1.7 0.00145 - - - 53 
1.8 - 2.40 0.140 0.058 46 
1.9 - 0.050 0.140 2.80 46 
7 - 0.005 0.120 25.0 46 
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Recently, Aerts and Overkleeft have taken the principles learned from these two activity based 
inhibitors and have developed several cyclophellitol and aziridine-type cyclophellitol based probes with 
fluorescent and biotin tags.51 The cyclophellitol based inhibitors contain the electrophilic epoxide 
warhead and, like CBE, form non-hydrolysable inhibitor-enzyme complexes. The structure of 
cyclophellitol 1.3 (Figure 8) is a compromise between that of glucose and CBE but unlike the Withers 
fluoro-glucose based inhibitors, in which carbon 2 was modified, a modification was made in compound 
1.5 to mimic a carbon 6 modification on glucose (Figure 8).52 This was done because, from structural 
biology studies, it is known modifications at carbon 2 prevent important enzyme-substrate interactions 
while bulky hydrophobic modifications at carbon 6 are tolerated, and in fact, enhance active site 
binding.44 Aerts and Overkleeft have also made N-acylated aziridine 1.6 and N-alkylated aziridine 1.7 
versions of epoxide 1.5 keeping all hydroxyl positions free.53 These probes might have been inspired by 
Withers’ conduritol aziridine glucosidase inhibitor 1.4 published in 1989. The activity probes were tagged 
with hydrophobic fluorescent reporter BODIPY and used to image GCase in cellular based assays. These 
probes exhibited very high binding affinities and stable enzyme-inhibitor complexes. In fact, these probes 
are some of the most potent inhibitors of GCase reported in the literature. The combination of a 
cyclophellitol backbone linked with an electrophilic epoxide warhead and hydrophobic tail make them 
very effective activity based probes for GCase. 
 All of the Aerts and Overkleeft activity based probes show high efficiencies for labelling GCase 
in vitro (Figure 8). Acyl aziridine 1.6 however, suffers from selectivity issues, having low nanomolar IC50 
values for GBA2 and GBA3 making it a broad spectrum -glucosidase probe.52 The acylated aziridine in 
1.6 is also quite a powerful electrophile rendering it prone to decomposition and high reactivity towards 
other human enzymes. Alkyl aziridine 1.7 was developed after 1.6 because alkylated aziridines are more 
stable then acylated ones. Although more stable, there is no information on its selectivity but conceivably 
1.7 has similar selectivity issues to its acylated cousin. Epoxide 1.5, however, shows excellent selectivity 
for GCase over GBA2 and GBA3.52 This is probably due to its different carbohydrate ring substitution 
pattern. The issue with epoxide 1.5, however, is its inability to penetrate the blood brain barrier (BBB) 
rendering it useless as an activity based probe for studying PD in vivo. The other issue with compounds 
1.5, 1.6 and 1.7 is the rather long and difficult synthesis associated with these compounds making their 
scaffolds unattractive for development of new derivatives. 
 Keeping in mind all the aspects of the previous activity-based inhibitors mentioned, an inhibitor 
with a simplified structure was synthesized and characterized by previous graduate student, Benjamin 
Adams, from the Phenix lab (Figure 8).46 The structure of this activity-based irreversible inhibitor is 
essentially an alkylated form of conduritol aziridine 1.4 and was easily prepared in 8 steps from 
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commercially available myo-inositol. Alkylation of the aziridine was chosen instead of acylation because 
alkylated aziridines tend to be more stable allowing for longer shelf life, less off-site reactions in a 
biological system and easier synthesis. Adams et al. was able to show that by lengthening the alkyl chain 
on the aziridine the potency of the inhibitor increased.46 The octyl-aziridine derivative 7 interestingly has 
a potency greater than any known inhibitor of GCase in the literature. Furthermore, it has been shown that 
7 has excellent in vitro characteristics in terms of its cell permeability and selective inhibition of GCase 
over GBA2 and GBA3. Also its inositol backbone may potentially allow it to be a substrate for inositol 
transporters promoting its passage across the Blood Brain Barrier (BBB). These desirable in vitro 
characteristics make compound 7 the lead compound for the development of GCase activity based probes 
in this thesis work. 
Probe Synthesis: Protecting Group Optimization 
  Despite these desirable in vitro characteristics, lead compound octyl aziridine 7 suffers from a 
synthesis that limits the types of derivatives that can be prepared and explored as activity based-probes. 
The synthesis includes a harsh LiAlH4 reduction to form the aziridine and employs Birch Reduction to 
remove the Benzyl ether (Bn) protecting groups.46 LiAlH4 cannot be used with easily reducible protecting 
groups and the Birch Reduction requires avoidance of aromatic fluorescent tags or radiochemical handles. 
Birch reduction is not easily compatible with radiochemistry considering the time constraints of 
radiochemistry and the shielding requirements associated with radiation (see Radiopharmaceuticals and 
PET Imaging). As a consequence, the synthesis of 7 will need to be modified in order to improve the 
flexibility of the synthetic chemistry to be amenable to the preparation of fluorescent or 18F labeled 
aziridines.  
 To improve the flexibility for the synthesis of aziridine 7, optimization of aziridine formation and 
final deprotection is required. Bn deprotection should be done rapidly and by using a technique that is 
amenable to radiochemistry and derivative production. Alternatively, new protecting groups should also 
be explored that can be easily incorporated, survive the entire course of the synthesis and can be quickly 
removed. The deprotection must also keep the aziridine and any fluorescent or radiochemical label intact. 
There are few protecting groups that can be used for this type of synthesis but three groups were chosen 
based on their promising stability to the synthesis and easy removal in the final steps. These groups are 
the tert-butyl dimethyl silyl ether (TBS), benzoate (Bz) or methoxy-methyl acetal (MOM) protecting 
groups with their chemical features summarized in (Figure 9).54 An improved synthesis will allow 
fluorescent aziridine derivatives to be developed for the study of GCase in vitro using appropriate cells 




Figure 9:  Summarization of potential protecting groups and their stability for synthesis of n-alkylated 
conduritol aziridines.54 
Imaging GCase in vitro: Development of Fluorescent Derivatives 
 As described above, fluorescent activity based probes for GCase have already been developed 
and used for studying GCase activity in vitro.53 These derivatives can be visualized by using fluorescent 
microscopy to produce colourful images showing where the probe accumulates in a cell while providing 
information on the activity and location of GCase inside living healthy cells or cell lines that mimic a 
diseased state. 
 Despite the development of the cyclophellitol activity-based fluorescent probes 1.5, 1.6, and 1.7 
for GCase reported by the Aerts and Overkleeft groups, we wanted to prepare fluorescent derivatives of 
N-alkyl conduritol aziridines. The epoxide cyclophellitol-based probes required lengthy and laborious 
synthesis while the N-acetylated cyclophellitols were found to be non-specific binders of GBA2 and 
GBA3.  In contrast, synthesis of the conduritol aziridine scaffold for 7 requires fewer chemical steps and 
initial experiments suggest that the N-alkyl aziridine scaffold is a potent and selective binder of GCase. 
Indeed, a fluorescent conduritol aziridine would prove valuable to determine the in cellulo specificity of 
these inhibitors since the probe would irreversibly label any related enzymes inside living cells.  Cell 
lysates can be easily extracted and the proteins separated by SDS-PAGE followed by analysis with a 
fluorescent imaging system to detect fluorescently labeled enzymes.   In addition, convenient synthetic 
routes for preparing efficient, selective and fluorescent N-alkylated aziridines would be useful for 
unraveling the biological role that GCase has in α-synuclein aggregation and could be used track the 
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enzyme activity in cells models of PD. Further, a fluorescent derivative can be used to help evaluate new 
chaperone therapies for improving GCase trafficking to the lysosome, a tool that would be beneficial for 
Gaucher Disease and PD research.  
 The death of many drugs that targets proteins in the brain result from their inability to cross the 
BBB. The BBB is a selective membrane, comprised of tightly joined endothelial cells, that selectively 
allow certain small lipophilic molecules to passively enter the brain and express proteins that actively 
transport hydrophilic substances.55 Considering the structure of compound 7, it cannot be considered a 
highly lipophilic compound and is unlikely to passively cross the BBB. This means that more lipophilic 
derivatives having fewer hydrogen bond acceptors or donors are needed to improve BBB permeability or 
find a derivative that is actively transported across the BBB. Luckily, aziridine 7 has been shown to be 
cell permeable by Adams et al. while recent and unpublished experiments performed by Dr. Shusheng 
Wang in the Phenix lab suggest that the conduritol aziridines are a substrate of the inositol transporters 
that are expressed in the BBB.46 To study BBB permeability in vitro and to reveal the compounds that are 
highly unlikely to enter the brain, it is possible to set up a trans-well assays that employ canine kidney 
cell lines that overexpress important protein pumps while also forming a tight monolayer of cells that 
mimics the BBB.81  Such as an assay would be valuable to identify those fluorescent and non-fluorescent 
aziridine derivatives that are efficient substrates in order to learn about the selectivity of these compounds 
towards p-Glycoprotein and multi-drug resistance protein pumps.  Both of these proteins are highly 
expressed in the BBB and are largely responsible for preventing moderately lipophilic molecules from 
entering the brain due to their pumping action. 
 To produce a fluorescent probe, a suitable fluorophore must be chosen that is compatible with the 
synthetic methods employed to prepare the compound. Since GCase is usually located in the lysosome, 
the fluorophore must also be stable at low pH (around 5) and maintain high fluorescence in the acidic 
environment if the probe is to be used to image living cells.12 Previous reports have shown that GCase 
readily accepts bulky and hydrophobic moieties within carbohydrate-based inhibitors or substrates so the 
structure of the fluorophore was not considered an important factor for binding affinity.56 For this project, 
three fluorophores were chosen to be investigated: BODIPY, Acridine and Dichlorofluorescein (Figure 
10). Each of these fluorophores are commonly used in cell biology studies, are highly fluorescent and are 
stable, even at low pH. By preparing derivatives of 7 coupled to these fluorophores we can potentially 
develop powerful molecular tools that can give insight into the location, function and activity of GCase 
inside living cells. 
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Figure 10:  Fluorophores that were chosen for labeling the conduritol aziridines based on their chemical 
stability and intense fluorescence at low pH values.   Conduritol aziridines bearing these fluorophores would be 
well adapted to fluorescent imaging of GCase activity within the lysosomes of living cells. 
Imaging GCase in vivo: Development of Radiopharmaceuticals for PET Imaging 
 In medical imaging there exists two main types of imaging techniques; anatomical imaging and 
functional imagining. Anatomical images are obtained when using imaging modalities like Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI) or Ultrasound. These techniques detect changes 
in tissue density and structure to produce high contrast images. Functional images are obtained when 
using molecular imaging modalities like functional MRI (fMRI), Single Photon Emission CT (SPECT) or 
Positron Emission Tomography (PET). These techniques produce images that reflect biochemical 
functions thus providing functional data instead of revealing the structures of tissues and organs.57 
For imaging GCase activity in the brain, the correct imaging modality must be chosen. CT , MRI 
and ultrasound can only give structural images so they cannot give any information of GCase activity on 
the molecular level.58 MRI contrast agents that are capable of imaging enzyme activity do exist, however 
no specific agents for GCase have been developed.  Furthermore, MRI has very low sensitivity requiring 
the injection of high amounts of contrast agent meaning toxicity of the MRI active probe can preclude 
human use.  The blood brain barrier (BBB) also represents an enormous challenge since most contrast 
agents require the use of heavy metals like gadolinium and are unlikely to enter the brain. Indeed, 
techniques have been improved to use functional MRI (fMRI) to study brain activity by measuring blood 
oxygen level dependent responses associated with neuron activity but this cannot give us a direct 
indication of GCase activity on the molecular level.57  
SPECT  is a widely used functional imaging technique but is not the modality of choice for 
imaging the brain. It is about 10 fold less sensitive than PET and requires the use of single-photon-
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emitting nuclides like 99mTc, 123I and 111In.59 These nuclides are difficult to incorporate into small 
molecular probes that would be expected to cross the BBB.60 With the exception of 123I, nuclides like 
99mTc and 111In are not commonly used to label small molecule tracers due to their large size lowering the 
affinity of potential tracers to the target enzymes. This reduction in binding affinity is attributed to the 
nuclides rather large size or their requirement to be chelated by a bulky chelating groups. These aspects 
make SPECT imaging agents inadequate for imaging the brain, especially when measuring enzyme 
activity that require a small molecule to enter a binding or active site within the interior of a protein.57 
 PET imaging has a rich history in imaging enzyme and receptor activity in the brain of humans 
and animals.61 PET imaging uses radiotracers labeled with positron emitting nuclides like 11C, 131I and 18F. 
Non-radioactive versions of these nuclides are commonly found in biological compounds, metabolites 
and many pharmaceuticals, so they can be incorporated into potential PET imaging agents without 
significant change to their biological properties, chemical properties or molecular weight. Indeed, many 
PET imaging agents intended to image targets in the brain have been developed using these nuclides. PET 
imaging agents for the brain are usually either small lipophilic molecules that passively diffuse across the 
BBB or molecules that mimic natural products that are actively transported across the BBB.57 Once in the 
brain, the emission of positrons can be detected with extremely high sensitivity allowing for microscopic 
amounts of radioactive tracer to be used.  
Positrons emitted by these isotopes in vivo will travel a very short distance before their 
momentum becomes essentially zero and they annihilate with an electron. This distance is called the 
positron range and is on average 0.3 mm for 18F in water. When a positron eventually makes contact with 
an electron they annihilate, producing two high-energy 511 keV photons released approximately 180° 
from each other. A PET camera works by detecting these coincident 511 keV photons with a circular ring 
of detectors positioned around the source in order to map out in 3 dimensions the location of the 
annihilation (Figure 11).59 By combining PET with a structural CT  image it is possible to overlay 
anatomical images with the radioactive signal thus allowing researchers or physicians the ability to 
identify the precise tissue or organ location of tracer uptake with a high degree of accuracy. In a full body 
Philips Gemini TF PET/CT scanner the resolution is approximately 1 cm after including all possible 
inaccuracies involved with the detector, patient scanning and other physical fundamental limitations of 




Figure 11:  Schematic diagram showing an 18F PET radiotracer used for functional imaging of the brain. 
Accumulation of the 18F labeled radio tracer in specific areas of the brain result in the emission of positrons that 
travel a short distance before annihilating with an electron to release 2 coincident 511 keV photons. After many 
decay events are detected, an image is produced that quantitatively reflects the tracer uptake in specific areas of the 
brain. 
 The high sensitivity of PET allows the micro dosing of the radiotracer in the microgram - 
nanogram range thus avoiding concerns of chemical toxicity of the imaging probe. For example, in an 
18F-FDG PET scan for the average adult, 2-3 μg of imaging agent is required for a full body scan.63 
Compare that amount to Ricin, a protein that is 6000 times more toxic than cyanide but still requires at 
least 500 μg to kill an adult man.64 At the micro dosing levels of the injected radiotracer, even drug 
candidates that were proven to be too toxic as pharmaceuticals can be radioactively labeled and used 
safely as PET imaging probes in humans and animals. 
The most harmful component of a PET imaging scan is the radioactive dose to which the patient 
is exposed to. When a 18F-FDG PET/CT is performed, most of the radioactive exposure comes from the 
anatomical CT  scan when compared to the dose from the PET tracer, cumulatively resulting in about 14 
mSv of dose in total.63 With more sensitive PET cameras coming onto the market, as well as new 
PET/MR instruments, exposure to ionizing radiation is becoming even less of a concern.  To put this dose 
into perspective, the annual background radiation exposure of an average person without additional 
exposure from manmade sources is approximately 4 mSv. Compare that to an airline crew that is 
estimated to receive an extra 2.19 mSv/y just from cosmic radiation.65 These values demonstrate that a 
PET/CT scan exposes a patient to about 10 times more radiation than what they would normally receive 
from annual background levels but overall, this dose is only moderately harmful to a patient since 
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multiple scans are not typically performed. The risk of damage from radiation is small considering the 
beneficial information a scan can provide to a physician for a patient.  
 There are several positron emitting isotopes available for the production of radiopharmaceuticals. 
The most commonly used positron emitting isotopes are 11C, 131I and 18F. To choose the best radionuclide 
for a GCase radiotracer two main things must be considered; 1) half-life of the nuclide and 2) the effects 
the radioactive atom will have on the probe’s biological activity. For this thesis work the isotope that will 
be incorporated for producing a GCase PET tracer will be 18F. This isotope is considered the isotope of 
choice for PET since it has the best image resolution and a sufficiently long 109.8 minute half-life 
compared to the short half life of 11C (20 minutes) and long half life of 131I (8 days). Having a longer half 
life helps enable radiochemical synthesis as reaction times can be increased as well as allowing time for 
purification, quality control and shipping to the small animal imaging facility. If the half life is too long, 
however, radioactive safety risks are higher because the injected animal or human remains radioactive for 
longer periods of time. 18F is also well suited for the labeling a drug or probe without affecting its 
biological activity greatly. This is because 18F is an isostere of both hydrogen and hydroxyl groups thus 
allowing great flexibility for its incorporation into biologically active molecules.61 
 Nucleophilic 18F is produced by a cyclotron, an instrument has the ability to accelerate a hydride 
anion by using alternating electromagnets called dees.  The negatively charged particle travels in a 
circular motion until the particle has enough kinetic energy to reach the outer diameter of the cyclotron 
chamber.  Once traveling at sufficient speeds, the hydride ion is stripped of its electrons and the positively 
charged proton rapidly bombards a target made of highly pure materials. For a source of nucleophilic 18F-
fluoride, 18O enriched water is used as the target material. Upon proton bombardment the 18O is converted 
into 18F after releasing a neutron. Production of radiopharmaceuticals with these isotopes has many 
challenges that have to be overcome compared with the production of regular pharmaceuticals. There are 
3 major things to consider when preparing radiopharmaceuticals: 
1) Safety: In the case of a positron emitting isotope like 18F, high energy (511 keV) gamma rays will 
be consistently produced as positrons annihilate with surrounding electrons. These gamma rays 
are harmful to humans in high doses and reasonable measures should be taken to limit exposure 
to this ionizing energy. This means using proper shielding (lead blocks) and manually handling 
low amounts of activity. Working around shielding or in an automated synthesis module 
obviously produces many obstacles that are non-existent in a regular chemistry laboratory. This 




2) Time : All radioactive isotopes have a characteristic half-life limiting the length of time for your 
chemical reactions. In the case of 18F the half-life is 109.8 minutes meaning the total reaction and 
purification time should not exceed one half life ideally. Incorporation of the 18F isotope should 
be done within the last steps of your synthesis and the reaction should be completed very quickly. 
Sometimes harsh reaction conditions are required to achieve this, potentially dramatically 
reducing yields. 
3) Concentration: In radiopharmaceutical production, stoichiometry is much different than in a 
typical organic reaction. For example, 1.5 mg of 18F would amount to approximately 5.5 million 
GBq. This amount of activity would be extremely harmful to people working with it  and require 
enormous amounts of energy to produce. Luckily since PET detectors are the most sensitive of 
the molecular imaging modalities, the amount of 18F required for a PET scan is less than 1 GBq. 
Although this is beneficial for limiting exposure to radioactivity it effects how the 
radiopharmaceuticals are produced. A typical production of 5.5 GBq of 18F equates to only 1.5 ng 
of isotope. This means that stoichiometric ratios of 18F to the chemical precursor is 1:104 or 1:105. 
Using such a dilute reactant makes it difficult to practically simulate the reaction in an organic 
chemistry lab using non-radioactive versions of the isotopes and clearly affects the rate of a 
reaction under pseudo-first order kinetics. Working on a ng scale with respect to 18F also means 
that even tiny amounts of impurities in the chemical precursors can react with the radionuclide 
and these side products, as well as the radiochemical product, cannot be characterized using 
traditional methods like NMR spectroscopy or TLC staining. Mass spectrometry is usually not an 
option as well because of the radioactivity involved. Characterization relies solely on the 
detection of radioactivity on a TLC or HPLC column and comparing its retention factor to that of 
a non-radioactive standard. 
Keeping these principles in mind it is first necessary to attempt to synthesize some fluorinated derivatives 
using non-radioactive 19F in order to prove the radiochemical reaction is potentially possible and can be 
done in a reasonable time frame. This is also necessary to have authentic samples for comparison on 








 It is clear from the literature that further studies are required to validate GCase as an attractive 
biomarker for detecting the early and accurate onset of PD and as a potential therapeutic target for drug 
development in patients with or without GBA1 mutations. To accomplish this the development of 
molecular tools is required to study GCase in vitro and in vivo. In this thesis, lead compound 7 will be 
used to develop synthetic routes to prepare activity based probes as molecular tools for studying GCase 
by completing the following objectives: 
 Optimize the synthesis of octyl aziridine 7 using an improved protecting groups strategy that is 
more flexible and suited for future probe development in terms of preparing aziridines having 
structural diversity, generating fluorescent derivatives and radiolabelling studies.  
 Synthesize fluorescently labelled derivatives of 7 that potently and irreversibly label GCase. 
 Synthesize non-radioactive 19F-labeled derivatives of 7 as PET tracer candidates and use them for 
enzyme kinetic studies to measure inactivation rates and authentic standards to determine TLC Rf 
and HPLC retention times for future radiolabeling experiments. 
 Develop radiochemical procedures for 18F labeling derivatives of 7 at the cyclotron facility. 
 
Figure 12:  N-alkylated conduritol aziridines bearing either a fluorescent moiety or an 18F tag for future 
imaging studies.  The hypothesized mechanism of action for labelling the active site of GCase is likely to occur 





Results and Discussion 
Previous Synthesis 
The synthesis of racemic N-alkylated conduritol aziridines was previously established by Adams 
et al as shown in Scheme I.46 This synthesis was concise and effective for obtaining the desired alkylated 
products to test these compounds as potent and irreversible inhibitors of GCase. Developing simple and 
efficient chemistry, starting from inexpensive starting materials, is noteworthy considering the numerous 
stereochemical issues that surround carbohydrate and inositol synthesis as well as stability issues and 
protecting group compatibility with the formation of aziridine rings.  The synthesis begins with 
regioselective isopropylidene protection of the hydroxyls on the C1 and C2 carbons of commercially 
available myo-inositol using a known procedure to obtain 1.66 Although compound 1 is produced in a 
regioselective manner the resulting procedure unavoidably forms a racemic mixture. Next, per-
benzylation of 1 into tetrabenzyl 2 and subsequently deprotection the isopropylidene under acidic 
conditions gave diol 3, both in quantitative yields (Scheme 1). The harsh acidic deprotection of 
isopropylidene is possible due to the great stability of the Bn protecting group in acid. After complete 
mesylation of 3, regioselective azidolysis of the mesyl group on the C2 carbon of inositol can be 
accomplished in DMF using NaN3. This selectivity is thought to arise from the bulky Bn protecting 
groups forcing the inositol ring to configure in such a way that the benzyl groups are positioned equatorial 
thus having the mesyl group at the C2 carbon axial while the mesyl at the C1 carbon remains equatorial 
(Figure 13). This is the thermodynamically favoured ring conformation and promotes SN2 substitution at 
the C2 position because the antibonding orbital of the leaving group is open for nucleophilic attack while 
in the C1 position the orbital is blocked inside the inositol ring. Despite this thermodynamic favourability, 
the overall yield from 3 to 4 is only 44%. Azide displacement rates of secondary mesylates are slow at 
low temperatures coupled with the presence of steric hindrance presented by the neighbouring multiple 
bulky Bn groups. High temperatures are required to compensate for slow conversion which increases the 
ability of the ring to flip and thus azidolysis of the C1 position to form a diazide by-product unavoidably 
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limits the yield of this step.
 
Figure 13: Tetrabenzylated inositol 3 after mesylation is thought to prefer a chair conformation where the Bn 
groups are predominately equatorial because of the reduction in steric hindrance. This is proven by reaction 
with sodium azide giving predominantly monoazide 4. 
 Azide 4 is reduced with LiAlH4 to form aziridine 5 in a 60% yield. This step, although effective 
for forming the aziridine, reduces the scope of different functional and protecting groups that can be used 
to prepare new derivatives and activity-based probes as many groups will not survive this powerful 
reducing agent. After reduction, the aziridine can be alkylated by simply heating 5 with K2CO3 and an 
iodo-alkane of differing length in DMF to yield various alkylated aziridines including 6. For final 
deprotection, although hydrogenolysis using Pd and H2 is not compatible with aziridines, tetra-benzylated 
6 can be deprotected successfully into lead compound 7 using Birch reduction. It was uncertain if the 
aziridine ring would survive Birch reduction conditions but Adams showed the ring to be stable under 
Birch conditions at -78°C.46 At this temperature conversion of 6 into unprotected aziridine 7 did not occur 
as quickly as anticipated but showed good conversion after 4 hours giving the final product in 55% yield. 
Adams has thus successfully demonstrated the ability to synthesize lead compound 7 which will act as the 
scaffold, in this thesis, to produce fluorescent and fluorinated derivatives as activity based probes to study 




Scheme 1: Protecting group discovery. (a) 2,2-Dimethoxypropane, pTsOH, DMSO, 90oC, 69%; (b) BnBr, NaH, 
DMF, 0oC – rt, 89% for 2; 1)TBSCl,, imidazole, DMF, 80°C, 2) TBSOTf, 2,6-lutidine, DMF, 80°C,55% for 8;, 
BzCl, DMAP, pyridine, rt, 95%, for 11; (c) 80% AcOH(aq), reflux, 95% for 3 and 12; TFA: CH2Cl2: H2O 4:4:1, 
0°C, 63% for 9; (d) i) MsCl, pyridine, 0oC – rt; ii) NaN3, DMSO, 75oC, 42%, (e) LiAlH4 0°C – rt, 60% for 5; Ph3P, 
TEA, THF: H2O (10:1), rt – reflux for 14; (f) iodooctane, K2CO3, DMF, 50°C, 59%; (g) Na(s) , NH3(l), THF, -78°C, 4 
h, 55%;  
Protecting Group Optimization 
Adams’ attempted Bn deprotection with standard hydrogenolysis conditions using hydrogen gas 
with a pallidum catalyst but was never successful in obtaining 7 as the desired product.46 This is probably 
because these standard hydrogenolysis conditions have been shown to either open, 67 rearrange68 or 
dealkylate69 an aziridine ring. To circumvent these issues, the Birch reduction was utilized instead.  
Removal of the Bn protecting groups is the biggest limitation in Adams’ synthesis for the diversity of 
future fluorescent and radiochemical derivatives because of the Birch reduction step. This deprotection 
method works well for producing the deprotected aziridine 7 as well as other alkylated compounds but it 
would not be compatible with any derivatives containing reducible functional groups like alkenes, alkynes 
and some aromatic groups like the kinds typically found in fluorescent probes. Furthermore, this 
technique would be very difficult to replicate in a cyclotron facility because of the complex setup and 
lengthy reaction times required to remove the Bn groups. Radiochemical reactions involving 18F are 
typically those that are less than 2 hours in total and whose protocol can eventually be adapted for an 
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automated synthesis module. Discovery of a faster and more versatile Bn deprotection method was 
required to generate a more diverse library of compounds based on lead compound 7. 
 Different Bn deprotection strategies were investigated that were shown to be more versatile and 
quicker than Birch reduction in the literature. Reductive cleavage using Li(s) with naphthalene in THF at -
20°C was employed because of previous reports in the literature where many functional groups that 
become reduced by Birch reduction still survive these conditions.70 After monitoring the reaction it was 
shown to have very low conversion rates from 6 to 7 even after long reaction times with no detectable 
product formed by TLC. Hydrogenolysis was attempted using triethylsilane as a different source of 
hydrogen compared to hydrogen gas.71 Using a less abundant source of hydrogen was thought to remove 
the Bn groups before a reaction with the aziridine ring occurred but conversion of starting material was 
not seen. FeCl3 in CH2Cl2 has been used for the deprotection of Bn groups but for 6 the strong Lewis acid 
produced a compound that did not move off the baseline on TLC suggesting decomposition of the 
aziridine.72 Despite testing several different conditions, an alternative Bn deprotection method was not 
discovered. This suggested that other protecting groups should be explored.  
 There are several different hydroxyl protecting groups available but not all groups possess the 
qualities desired for this synthesis. The protecting groups must be installed onto neighbouring hydroxyl 
groups on an inositol ring, must survive the entire synthesis and must be removed easily  when required. 
In addition, they must remain stably attached to the desired hydroxy group since some protecting groups 
are known to transfer to adjacent hydroxyls making them inappropriate for inositol chemistry. The TBS 
group was the first alternative protecting group chosen to incorporate onto compound 2 because of its 
stability to LiAlH4, the reagent used in the aziridine formation step. Also its simplistic removal using 
TBAF was considered to be favoured for the final deprotection step. TBS is one of the bulkier silyl 
protecting groups, giving it enhanced stability. However, the steric bulk of the TBS group appeared to be 
a problem early on in the synthesis. Interestingly, treatment of isopropylidene 1 with an excess of 
imidazole and TBSCl yielded a tri-silyated compound instead of desired tetra-silyated 8. Installing the 
fourth TBS group was extremely difficult due to steric crowding. Although tetra TBS 8 could be obtained 
using the expensive TBSOTf instead of TBSCl a more potent electrophile, the isolated yields were not 
ideal considering this is only the second step in the synthesis. Despite having concerns that the TBS group 
would be removed under harsh acidic conditions, short treatment of 8 using TFA: CH2Cl2: H2O 4:4:1 at 
0°C allowed the isopropylidene to remain intact in order to get 9 in 63% yield. Mesylation of diol 9 was 
found to proceed smoothly, however, azidolysis, was unsuccessful as conversion of the mesylate into 10 
was not possible. Increasing temperature was not sufficient to enable conversion into 10. This is thought 
to be because of the extreme bulkiness of the TBS groups crowding the site of nucleophilic attack. 
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Inability to form the azide 10 using sodium azide led to the discard of this protecting group strategy for 
preparing fluorescent or radioactive derivatives. 
 Another protecting group that seemed like an obvious choice was the Bz ester protecting group. 
The Bz protecting group is the ester cousin of the Bn ether protecting group having similar size and 
structure but much higher lability to basic conditions. This conceivably would allow for efficient 
deprotection without destroying the acid labile aziridine group. Reaction of isopropylidene 1 with benzoyl 
chloride in presence of DMAP successfully generated tetrabenzoyl 11 using a published procedure 83 and 
deprotection of the acetal using acidic conditions proceeded smoothly to yield the tetrabenzoyl 12 in 
quantitative yield.  However, reaction of the dimesylate with NaN3 yielded many side products resulting 
in low isolated yield. The formation of many different products during this reaction could be due to the 
Bz group’s tendency to migrate to neighbouring hydroxyl groups or its propensity to act as an electrophile 
towards, for example, a nucleophile like sodium azide.54  
 From these experiments it was clear that careful choice of the protecting group is required taking 
into account steric bulk and chemical reactivity. Although the silyl ethers were stable, they were too bulky 
leading to difficulty in preparing the tetra TBS inositol 8 and unsuccessful preparation of azide 10.  The 
Bz ester protecting groups appeared to produce many side products upon reaction with higher 
temperatures and nucleophilic azide present. Since the ether based Bn protecting group strategy was 
successful for the synthesis of the N-alkyl aziridines prepared by Adams, we decided to explore other 
ether-based protecting groups. The MOM protecting group is another ether based protecting group that is 
highly stable to basic, reducing and oxidizing conditions while still being mildly stable to acidic 
conditions.54 To avoid any potential issues of acidic lability of the MOM ethers, benzaldehyde acetal was 
used to protect myo-inositol regioselectively forming 15 using a known literature protocol74 instead of 
forming the isopropylidene. The MOM group was easily installed in quantitative yield to get 16 and the 
benzaldehyde acetal was removed using hydrogenolysis with hydrogen gas and palladium catalyst to 
yield the diol 17 also quantitatively (Scheme 2). Mesylation of the diol into 18 proceeded smoothly 
followed by azidolysis performed in DMF to form the expected mono azide that was difficult to isolate by 
traditional methods like silica gel chromatography or recrystallization. This is most likely due to the 
smaller size of the MOM group not delivering the same reaction selectivity and chromatographic 
separation as with the Bn group as a result of the decreased steric hindrance and increased conformation 
flexibility of the ring. Formation of additional side products associated with this reaction have increased 
and may be very similar in polarity to the desired product making purification more difficult. Despite not 
being able to characterize the reaction products using NMR spectroscopy, the crude materials were used 
directly for azide reduction to form aziridine 19. Instead of using LiAlH4 we opted to use Ph3P and added 
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water to perform a Staudinger reduction of the azide to subsequently obtain aziridine 19. Compound 19 
was successfully isolated in 58% yield over 2 steps. Considering safety, the reaction efficiency and 
simplicity of the Staudinger reaction for forming the aziridine ring, it was deemed the new standard 
compared to using LiAlH4 reduction which is water sensitive, more difficult to work-up and much more 
dangerous to handle.  
N-alkylation of the aziridine was performed using iodooctane and N,N-diisopropylethylamine 
proceeding smoothly to obtain 20 in 55% yield. Global deprotection of 20 was difficult under acidic 
conditions such as with TFA or HCl because high concentrations of acid were required to remove all 
MOM groups in a reasonable time frame but we observed by TLC the conversion rate to product to be 
just as quick as the decomposition of the product. This is probably due to acid catalyzed opening of the 
aziridine ring. As anticipated, MOM groups can also be removed using a strong Lewis acid like TMSBr. 
By using 20 equivalents of TMSBr, anhydrous acetonitrile and an inert atmosphere at 0°C, deprotection 
of fully protected 20 into N-alkylated aziridine 7 occurred at an impressive 83% yield. More interestingly 
this reaction could be completed in about 30 - 40 minutes. Careful workup of this reaction was important 
as saturated NaHCO3 was required to hydrolyze the bromo intermediate formed during this reaction and 
to eliminate any HBr that may form. The MOM protecting group demonstrated to be an adequate 
substitute for the Bn group for carrying out the complete synthesis of an N-alkylated conduritol aziridine. 
It also proved to be superior to the Bn group because of its quick and simple deprotection. Synthesis with 
MOM as the protecting group is anticipated to yield a large diversity of derivatives and to be much more 







Scheme 2: Complete synthesis of 7 using the MOM protecting group.  (a) Dimethoxy toluene, pTsOH, DMF, 
120oC, 70%; (b) MOMCl, DIPEA, DMF, 65oC, 95%; (c) H2 (g) (1 atm), Pd/C, EtOAc 95%; (d) MsCl, pyridine, 0oC – 
rt, 95%; (e) i) NaN3, DMF, 80oC, ii) Ph3P, TEA, THF: H2O (10:1), rt – reflux, 58% over 2 steps; (f) iodooctane, 
DIPEA, acetonitrile, reflux, 55%; (g) TMSBr, acetonitrile, 0oC, 30 min, 83%;  
Fluorescent Derivatives 
Having established a new synthetic method for generating racemic N-alkylated conduritol 
aziridines through utilization of the MOM protecting group, the synthesis of fluorescent derivatives that 
are able to probe GCase activity was pursued next. Indeed, any fluorescent microscopy techniques that 
could track GCase location and activity in live cells is important for studying its involvement in PD since 
trafficking of the enzyme to the lysosome is apparently disrupted. We envisioned that attaching a 
fluorescent reporter molecule appended to the aziridine ring would result in an efficient activity-based 
probe that would irreversibly and selectively bind to GCase inside living cells. Additionally, recent 
reports in the literature have shown that bulky groups are well-tolerated and even preferred in the 
hydrophobic binding pocket of GCase.56 Consequently, it is not unreasonable to assume that the potent 
GCase binding affinity and selectivity of the N-octyl conduritol aziridine 7 should be retained after 
incorporation of a fluorescent reporter. As mentioned before it is important to choose a molecule that 
maintains high fluorescence at the low pH present in the lysosome. This is why BODIPY, Acridine and 
Dichlorofluorescein were chosen as the fluorophores used to prepare the fluorescent aziridine derivatives. 
 BODIPY is a hydrophobic fluorophore that has a large quantum yield and has strong fluorescence 
that is insensitive to changes in pH. LysoTracker® is a BODIPY derivative designed to accumulate in the 
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acidic lysosomes and is the gold standard routinely used for fluorescent tracking of the organelle in live 
cell studies. As shown in Scheme 3, we found that alkylation of 19 with bromo-BODIPY 21a under basic 
conditions and sodium iodide effectively produced 21 with a 50% yield (Scheme3). Although this was a 
highly encouraging result that produced the first fluorescent derivative in our lab, deprotection of the 
MOM ethers of 21 into the aziridine 22 was unsuccessful. Deprotection with TMSBr yielded an insoluble, 
non-fluorescent compound that that remained at the baseline of a TLC. The formation of an insoluble 
product is probably due to the strong Lewis Acid nature of TMSBr and its ability to react with the boron 
difluoride component in BODIPY. Other deprotection conditions were investigated to remove the MOM 
ethers such as various combinations of TFA and HCl in different solvents like CH2Cl2, THF and Dioxane. 
The various experimental conditions were found to either yield complex mixtures of partially deprotected 
compounds or non-fluorescent derivatives resulting from degradation of the BODIPY fluorophore. Since 
MOM deprotection in the presence of BODIPY was not compatible, coupling of BODIPY after 
deprotection was attempted. Alkyne 35 was synthesized (discussed later) and used for Sonogashira 
coupling by using 4-iodo-BODIPY-benzene 23a to make 23. Only starting material remained, despite 
trying both anhydrous and refluxing conditions. 35 was also used to attempt a Huisgen 1,3-Dipolar copper 
catalyzed cycloaddition using BODIPY-azide 24a to obtain 24. Despite several solvent combinations with 
DMF, H2O or tert-Butanol along with different catalyst concentrations of CuSO4, sodium ascorbate and 




Scheme 3: Towards BODIPY inspired fluorescent derivatives.  (a) 21a, DIPEA, NaI, acetonitrile, reflux, 50%; 
(b) TMSBr, acetonitrile, 0oC; (c) 23a, Pd(PPh3)4, CuI, TEA, DMF, reflux; (d) 24a, CuSO4, sodium ascorbate, 
TBTA, DMF: H2O (4:1).  
 Since all attempts to incorporate BODIPY onto the aziridine scaffold failed, a new fluorescent 
reporter molecule was chosen.  Acridine Orange is a versatile dye used for staining DNA, RNA in 
eukaryotes and prokaryotes.73 It is highly fluorescent at low pH which also makes it useful for studying 
the acidic environment of the lysosome. 9-amino-Acridine (not shown) is commercially available and has 
been used as a nucleophile for coupling Acridine to certain drug-like molecules. These reactions, 
however, require harsh reaction conditions because of the poor nucleophilicity of the primary amine 
connected to the Acridine backbone and the delocalization of the non-bonding electrons into the aromatic 
rings. 9-amino-Acridine heated at 90°C with mesylated aziridine 37 (Scheme 5) and under basic 
conditions (NaH or CsCO3) showed no reaction as 9-amino-Acridine remained and 37 was hydrolyzed. 
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Since the nucleophilic substitution reaction of mesylated aziridine did not produce the desired fluorescent 
compound, Sonogashira coupling was attempted instead. 9-iodo-Acridine 28a was prepared from 9-
chloro-Acridine and immediately reacted with the MOM protected alkyne 32 under Sonogashira 
conditions successfully producing fluorescent aziridine 28 in 68% yield (Scheme 4). MOM deprotection 
using standard TMSBr conditions gave the deprotected fluorescent aziridine 29 in 66% yield, the first 
fluorescent N-alkylated conduritol aziridine derivative synthesized in our lab. The excitation and emission 
maxima were found to be 355 nm and 455 nm respectively, giving 29 fluorescence in the blue range of 
the visible light spectrum (Figure 14). 
 
Figure 14: Emission and excitation spectra for 29 measured in a 96 well plate using a Biotek Synergy 4 hybrid 
multi-mode reader. Fluorescence was measured using 1 μM final concentration of compound 29 in 50 mM NaOAc 
buffer at various pH. Fluorescence from buffer without any compound was used as a blank and subtracted from all 
measurements. The sensitivity of the instrument was set at 100 and the measurements were done in 10 nm 
increments. The Exmax = 355 nm and the Emmax = 455 nm at pH 5. 
 Due to the success of the Sonogashira coupling to prepare the Acridine labeled aziridine as 
described above, similar chemistry was utilized for coupling of another fluorophore, Dichlorofluorescein. 
This fluorophore is more photostable than fluorescein and the electron withdrawing halogens reduce the 
pKa of the phenolic protons thus allowing the compound to be highly fluorescent at low pH. The 
Dichlorofluorescein was acetylated prior to Sonogashira coupling to prevent the opening and closing of 
its lactone ring and increase its solubility in organic solvent. An acetylated iodo derivative of 
Dichlorofluorescein 30a was prepared as a 5(6) isomer in the interest of available resources and time 
using a known protocol.80 31 was coupled with alkyne 32 using Sonogashira conditions (Scheme 4). The 
reaction proved to be slower than in the similar reaction with the 9-iodo-Acridine but the coupling was 
successful nonetheless to produce compound 30 in a 31% yield. Upon MOM deprotection with TMSBr, 
the reaction solution became very fluorescent, suggesting the acetate groups were also being removed. 
Nevertheless, acetate removal was assured by stirring the crude product mixture in MeOH and K 2CO3 for 
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1 hour after quenching. After silica gel column purification, the second fluorescent derivative 31 was 
obtained in 90% yield. The excitation and emission maximums were found to be 510 nm and 525 nm 
respectively, giving 31 fluorescence in the green range of the visible light spectrum (Figure 15). 
 
Figure 15: Emission and excitation spectra for 31 measured in a 96 well plate using a Biotek Synergy 4 hybrid 
multi-mode reader. Fluorescence was measured using 1 μM final concentration of compound 31 in 50 mM NaOAc 
buffer at various pH. Fluorescence from buffer without any compound was used as a blank and subtracted from all 
measurements. The sensitivity of the instrument was set at 100 and the measurements were done in 10 nm 






Scheme 4: Successful synthesis of Acridine and Dichlorofluorescein inspired conduritol aziridine derivatives. 
(a) 28a, Pd(PPh3)4, CuI, TEA, THF, reflux, 68%; (b) TMSBr, acetonitrile, 0oC, 66%; (c) 30a, Pd(PPh3)4, CuI, TEA, 
THF, rt, 31%; (d) TMSBr, acetonitrile, 0oC, 90% 
Having two different fluorescent derivatives is beneficial simply for the fact that their behaviour 
in a biological system is unknown until cellular experiments are performed. It is unknown how the 
fluorophore will affect binding to GCase, permeability of the aziridine compound to enter into the cell, 
permeability into the lysosome and tendencies to become trapped in different compartments/organelles of 
the cell. From the fluorescence spectra in Figure 15 and Figure 16 it already appears that the 
Dichlorofluorescein derivative 31 will be less sensitive to low pH in terms of its fluorescence intensity 
and therefore in terms of its ability to ionize. Acridine and Dichlorofluorescein are different in the sense 
that Acridine possesses a nitrogen within its ring structure with a pKa of around 5.6 resulting in a 
significant percentage of the fluorophore becoming positively charged in the acidic environment of the 
lysosome thus affecting binding affinity to GCase.  In addition, weakly basic amines are known to 
spontaneously accumulate in the acidic lysosome (a process called lysosomotropism) where they become 
protonated and are unable to passively diffuse by the lysosomal membrane. Such behavior of a 
fluorescent probe intended to image a lysosomal enzyme could potentially result in false positive signal 
due to the lysomotropism.  On the other hand, Dichlorofluorescein has two ionisable phenols and a 
carboxylic acid moiety with a pKa of approximately 4.8 resulting in predominantly an anionic species 
Exmax   = 355 nm 
Emmax = 455 nm 
Exmax   = 510 nm 
Emmax = 525 nm 
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inside in a living cell. Besides having different chemical properties, the two fluorescent derivatives also 
fluoresce at different wavelengths which is useful to avoid overlap with other fluorescent compounds in 
an in vitro experiment such as DAPI (for revealing the nucleus of a cell) or LysoTracker® dye for 
staining lysosomes. Both of these dyes would be useful in future cell based imaging experiments to 
validate the fluorescent probes.  The fluorescent probes synthesized in this section have the potential to 
monitor GCase trafficking inside living cells, a potential mechanism of PD progression.   
Radioactive Derivatives 
 PET imaging can be used to non-invasively track GCase activity in a living biological organism 
like a mouse or human. In order to do this, a radioactive derivative of 7, labeled with a PET isotope like 
18F, needs to be developed to be employed as a radiopharmaceutical imaging agent.  
The first fluorinating strategy attempted was Sonogashira coupling using commercially available 
4-fluoro-iodobenzene (FIB). Radiochemical 18F fluorination using 18F-FIB is a technique shown to be 
successful for other compounds, including highly polar compounds, similar to the deprotected conduritol 
aziridines.75 The MOM protected aziridine 19 was alkylated using 6-iodo-alkyne to cleanly obtain alkyne 
32 in 30% yield (Scheme 5). Subsequent Sonogashira coupling with FIB was shown to be efficient in 
refluxing acetonitrile, yielding aryl-fluorinated aziridine 33 nearly quantitatively after only 30 minutes 
reaction time. Then, fluorinated derivative 33 was deprotected using TMSBr deprotection to yield the free 
aziridine 34 in 49% yield. These were encouraging results, since high yields and rapid reactions are 
required for radiochemistry using the short-lived 18F isotope. Interestingly, it was found that the MOM 
groups of 32 could be deprotected before Sonogashira coupling to give alkyne 35, an extremely polar 
derivative. For Sonogashira coupling of 35 with FIB the solvent was switched to 1:1 acetonitrile: water to 
compensate for the increased polarity of the reactants and to ensure solubility. It was surprising that this 
Sonogashira coupling proceeded in the presence of water as Sonogashira couplings are often required to 
be anhydrous. The coupling of FIB with 35 was just as efficient as with 32 to also yield compound 34 





Scheme 5: Synthesis of fluorinated conduritol aziridine authentic standards for radiochemistry .  (a) 6-iodo-1-
hexyne, DIPEA, acetonitrile, reflux, 30%; (b) FIB, Pd(PPh3)4, CuI, TEA, acetonitrile, reflux, 15 min, 95%; (c) 
TMSBr, acetonitrile, 0oC, 30 min, 49%; (d) TMSBr, acetonitrile, 0oC, 30 min, 95%; (e) FIB, Pd(PPh3)4, CuI, TEA, 
acetonitrile: H2O 1:1, reflux, 15 min, 95%; (f) 9-bromo-1-nonanol, DIPEA, NaI, acetonitrile, reflux 35%; (g) MsCl, 
TEA, CH2Cl2, 0° - rt, 90%; (h) TEAF, acetonitrile, reflux, 15 min 56%; (i) TMSBr, acetonitrile, 0oC, 30 min, 75% 
 After having promising results using Sonogashira coupling with FIB, efforts were made to utilize 
these conditions for radiolabelling alkyne 35. To investigate this reaction 18F-FIB must be synthesized and 
then conjugated to alkyne 35 using Sonogashira coupling. The synthesis of 18F-FIB has been published by 
Wuest et al. and they have shown excellent results from using commercially available precursor (4-
iodophenyl)diphenylsulfonium triflate 40 (Scheme 6).76 Using a GE TRACERlab FX N PRO automated 
synthesis module, 18F-FIB 41 was made by azeotropically drying a mixture of 18F fluoride in 
K2.2.2/K2CO3, adding the diaryl sulfonium precursor 40 in acetonitrile and reacting this mixture for 15 
minutes at 90°C. The reaction was diluted with water, loaded onto a Waters (Milford, MA, US) Sep-Pak® 
tC18 plus light cartridge, washed with water and crude 18F-FIB 41 was eluted to a separate reactor using 
acetonitrile. This reactor contained alkyne 35 and all the reagents required for Sonogashira coupling. The 
reaction was heated to 90oC for 20 minutes, cooled, filtered using a 0.2 μm Nylon filter then analyzed 
using HPLC. Unexpectedly, 42 was not formed by this reaction, despite the successful reaction using 
non-radioactive 19F-FIB. This was confusing considering the successful Sonogashira coupling used to 
make the non-radioactive fluorinated standards in the laboratory. To investigate this reaction further, 
fluorination of diphenylsulfonium triflate 40 into 18F-FIB 41 was investigated using 19F fluoride. It 
appeared, under the exact same conditions except stoichiometric amounts of fluoride instead of 
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radiochemical amounts of fluoride were used, FIB was not synthesized according to TLC and NMR using 
the same reaction conditions as reported earlier. Instead, a compound having a different but similar TLC 
Rf value to 19F-FIB always appeared. After analyzing the NMR spectra of this side product (Appendix 1) 
it was confirmed that this species was not 19F- FIB nor the starting material. The Wuest group was 
contacted for some insight but it seemed they have never tried this synthesis using 19F fluoride because 
19F-FIB is commercially available and the radiochemical labeling reactions reliably worked as they could 
show the 18F-FIB was being synthesized through co-injection experiments using HPLC. Furthermore, 
they used the purified 18F-FIB to conduct successful Sonogashira couplings to prepare a variety of PET 
tracers.75 
 
Scheme 6: Sonogashira radiolabelling of compound 35. (a) K[18F]F K222, K2CO3 , acetonitrile, 90°C, 15 min; (b) 
35, Pd(PPh3)4, CuI, TEA, acetonitrile: H2O 1:1, 90°C, 20 min.  
 
 The part of the Wuest protocol that was changed for the formation of 42 was the absence of an 
HPLC purification step after formation of 18F-FIB 41. This step was omitted because it was assumed that 
upon washing 41 on a Waters tC18 Sep-Pak that the only compound being retained would be 
18F-FIB. 
Indeed, upon characterization of the contents in the reaction mixture after purification on a Waters tC18 
Sep-Pak it was found that the starting material diphenylsulfonium triflate 40 was also retained despite its 
polarity and would contaminate the Sonogashira coupling step. Considering that the 18F isotope is present 
at g to ng levels in a radiochemical reaction, even having small amounts of contaminating 40, a potent 
electrophile, could possibly interfere with the Sonogashira coupling of 41 with 35 thus preventing the 
preparation of the PET tracer.  
Considering the automated synthesis modules were not setup to do an intermediary HPLC 
purification, attempts were made to try and purify the crude reaction mixture of the fluorination of 40 
without having to do a HPLC purification in between reactions. Solvent conditions were optimized so that 
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a Waters silica gel Sep-Pak could be used to elute 18F-FIB but trap the positively charged diaryl 
sulphonium triflate 40 before entering the second reaction. Different solvents were tested on the silica gel 
Sep-Pak to find that diethyl ether appeared to not elute 40 from the cartridge while completely eluting 
FIB. This was encouraging because instead of purifying 18F-FIB 41 using HPLC, a silica gel cartridge 
may be used to remove 40 plus other polar impurities before the second reaction to takes place. 
Unfortunately, upon HPLC analysis of the 18F-FIB 41 reaction mixture it appeared purity did not differ 
substantially between a mixture purified with a silica gel cartridge and without. The UV trace at 254 nm 
did not differ significantly between the crude mixture purified with and without the silica Sep Pak despite 
TLC analysis showing no traces of 40 (Figure 16). It was obvious that either some of 40 was still passing 
through or some other impurity existed that could not be removed without an HPLC purification. Since 
the cyclotron facility in Thunder Bay is not currently set up properly for doing HPLC purification in the 
middle of an automated synthesis, this strategy was set aside to be pursued in the future. 
 
Figure 16: HPLC chromatogram of the reaction mixture of diaryl sulphonium triflate 40 with KF, K 2CO3, 
K2.2.2 in acetonitrile at 90oC for 15 minutes after washing on a Waters tC18 Sep Pak. A) without additional 
Waters silica gel Sep Pak purification and B) with additional Waters silica gel Sep Pak purification. The mixture 
was co-injected with commercially available FIB which can be seen at around 28 minutes. HPLC separation was 
performed using a gradient elution as follows: (A: water; B: CH3CN; 0 min 50% B, 8 min 50% B, 21 min 80% B). 
The flow rate of the system was 3 mL/min. 
 The most common fluorination strategy to prepare low levels of PET tracers for initial in vivo 




displacement of a leaving group installed onto a precursor. Commonly used leaving groups for this type 
of chemistry are mesyl and tosyl groups. Alkylating the MOM protected aziridine 19 with 9-bromo-
nonanol successfully yielded 36 and upon treatment with mesyl chloride 37 was obtained in excellent 
yield. The mesylated precursor 37 was treated with tetra ethyl ammonium fluoride (TEAF) in refluxing 
acetonitrile to get fluorinated 38 with a 56% yield in 15 minutes. MOM deprotection with TMSBr using 
previously optimized conditions afforded fluorinated N-alkylated conduritol aziridine 39 with a 75% yield 
in approximately 40 minutes (Scheme 5). Given the high yields and short reaction times, this synthetic 
method also shows promise for 18F radiochemical labelling. 
 
Scheme 7: Radiolabelling of 37 using nucleophilic fluoride to perform a mesyl substitution . (a) [18F]TEAF, 
acetonitrile, 90°C, 15 min; (b) 1) TMSBr, acetonitrile, rt, 20 minutes, 2) saturated NaHCO3. 
 Considering the hardships presented by the automated synthesis modules, which are typically 
reserved for clinical translation of a PET tracer, this reaction was attempted using low levels of activity (≈ 
300 MBq) for manual radiochemical synthesis. For this reaction the 18F in H2
18O was first loaded onto a 
Waters (Milford, MA, US) Sep-Pak® light QMA anion-exchange cartridge (filled with quaternary 
ammonium chloride polymer) and the cartridge was washed with 5 mL of hexanes to remove all water 
according to a known procedure.77 The cartridge was then eluted upside down (to improve 18F elution 
yield) using tetra ethyl ammonium bicarbonate (TEAB) in pure acetonitrile. This allowed for elution of 
the 18F without any azeotropic drying to remove contaminating water which would interfere with the 
nucleophilic substitution reaction. The 18F-TEAF was mixed with 37 and heated on a thermomixer for 15 
minutes at 90°C (Scheme 7). Radio-TLC suggests that the 18F-fluorine was successfully incorporated into 
the aziridine compound (Figure 17). The deprotection was attempted by cooling the mixture to room 
temperature and adding TMSBr directly. The mixture was stirred at room temperature for 20 minutes then 
quenched with saturated NaHCO3 The mixture was analyzed by radio-TLC but it appeared decomposition 
had occurred as the radioactive peaks were only detected at the baseline despite the authentic standard 
having an Rf above the baseline. Time permitting, it would be useful to try different deprotection 




Figure 17: Radio-TLC chromatogram showing TLC after reaction of Mesylate 37 to get fluorinated 43.  
Compound 43 was shown to match the Rf of authentic standard 38 of 0.70 in 2:1 EtOAc: Hexanes. 
Radiochemical purity appears to be over 90%. 
Enzyme Kinetics – Measuring Inactivation Rates of Novel Inhibitors 
To compare the rate of GCase inactivation of fluorinated derivatives 34 and 39 to that of lead 
compound 7, a range of eight concentrations of the inhibitor predicted to surround the K i value were 
incubated with Cerezyme® (recombinant GCase), and the reaction mixtures were assayed for residual 
enzyme activity at different time intervals. Small aliquots of these reaction mixtures were withdrawn and 
diluted 20-fold in 96 well plates containing a final concentration of 4 mM of the substrate 2,4-DNP-β-D-
Glc. Dilution of the reaction mixture effectively halts further inactivation by diluting the inhibitor and 
active site competition by excess substrate. Residual enzymatic activity at different time points and 
concentrations was monitored by quantifying the release of 2,4-DNP after 2,4- DNP-β-D-Glc cleavage by 
Cerezyme®.  
In Figure 18, ki is the rate constant for inhibitor inactivation of an enzyme and K i (k-1/k1) is the 
dissociation constant for the inhibitor with the enzyme otherwise known as the binding affinity.78 The 
ratio ki/Ki is an indication of the efficiency of an inhibitor, taking into account both binding efficiency and 

















Figure 18: General depiction of an irreversible inhibitor binding to an enzyme. The rate constant of the of the 
inhibitor dissociating from the enzyme (k-1) over the rate constant of the inhibitor binding to the enzyme (k1) gives 
the dissociation constant Ki for the inhibitor to the enzyme. Smaller Ki values equate to higher binding affinities. 
Reaction of the enzyme with the inhibitor can occur after binding to form an irreversible enzyme-inhibitor complex. 
The rate of this reaction is ki. The ratio of ki/Ki is an overall measure of the efficiency of an irreversible inhibitor.  
The velocity data obtained from this inactivation assay was fit, using the GraphPad Prism 
software, to Equation 1 a one phase decay equation. From this equation it is possible to obtain an 
observed rate constant kobs for the inactivation of Cerezyme® by the inhibitors tested. The observed rate 
constant would allow for the determination of enzyme kinetic parameters k i and Ki.  
Equation 1:   𝑌 = (𝑌0 − 𝑃𝑙𝑎𝑡𝑒𝑎𝑢)𝑒
(−𝑘𝑜𝑏𝑠)𝑥 +𝑃𝑙𝑎𝑡𝑒𝑎𝑢 
Inactivation data would follow Equation 2 if saturation of the enzyme’s active site occurs at high 
inhibitor concentrations. This allows for separation of k i and Ki values. The data will have an observable 
curve when this equation can be used effectively. 




In cases where saturation cannot be observed due to rapid inactivation of the enzyme at high 
concentrations of inhibitor, the data will appear linear and Equation 3 must be used which gives the 
second order rate constant as the ratio of k i to Ki. 




All of the inhibitors tested followed Equation 3 demonstrating their highly efficient rate of 
inactivation. The kinetic analysis of the aziridine inhibitors can be seen in Figure 19. The rapid 
inactivation of Cerezyme® by the inhibitors tested in this work prevented the determination of individual 
Ki and ki values. This is because at saturating concentrations of inhibitor, the enzyme is almost 
instantaneously inactivated. As a result, we could only determine the second order rate constant of 
inactivation ki/Ki, a parameter still useful to compare the efficiency of fluorinated probes 34 and 39 to 
lead compound 7. This was not surprising as Adams et al. demonstrated these N-alkylated conduritol 
aziridines to be very efficient inactivators of GCase. It was found that the k i/Ki values for butyl, hexyl and 
octyl (7) conduritol aziridines to be 3.8 ± 0.1 mM-1min-1, 640 ± 30 mM-1min-1, and 3670 ± 70 mM-1min-1 
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respectively.46 It is clear from this data that as carbons are added to the alkyl chain binding affinity 
increases dramatically.  
  From examining the ki/Ki values obtained from the inactivation experiments it is clear that the 
binding affinities 34 and 39 are not much different than that of lead compound 7 (Figure 19). The ki/Ki 
values for 7, 34, and 39 were found to be 6600 ± 500 mM-1min-1, 5100 ± 100 mM-1min-1, and 7700 ± 400 
mM-1min-1 respectively. This demonstrates how potency was conserved upon installation of the fluorine 
or fluorinating handle.  With a ki/Ki of 77% ± 2% that of lead compound 7 the Sonogashira coupled 
derivative 34 appears to be slightly less efficient at binding to Cerezyme® than 7 possibly due to the 
rigidity imposed by the aromatic/alkyne structure reducing interaction with the hydrophobic binding site 
in GCase. Alternatively, with a ki/Ki of 116% ± 5% that of lead compound 7, 39 appears to be slightly 
more efficient at inactivating Cerezyme®, possibly due to the increased length of alkyl chain where 
Adams et al. has previously shown to significantly impact the binding affinities of these alkylated 
conduritol aziridines.46 This does give rationale to synthesize conduritol aziridines with longer alkyl 
chains in the future to try and discover the upper limits of this trend. Regardless, this kinetic information 
shows that fluorinated derivatives 34 and 39 do not suffer from decreased binding affinity to GCase and 
radioactive derivatives have promise as PET imaging probes for imaging GCase in living organisms. In 
fact, [11C]-deprenyl is an irreversible inhibitor used to PET image monoamine oxidase B in the human 
brain. Since [11C]-deprenyl was measured to inactivate monoamine oxidase B with a ki/Ki of 6400 mM
-
1min-1,79 we are confident that the fluorinated PET tracer candidates prepared in this thesis have sufficient 
inactivation rates to be used as PET tracers for imaging GCase in the brain of animals or humans 
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Figure 18: Inactivation of GCase experiment.  Plot of 
remaining enzyme activity over time at the indicated inhibitor 
concentrations fitted to a one phase decay equation for A) 7, 
C) 34, E) 39. Plots of the observed rate constants of 
inactivation versus the concentration of inhibitor for B) 7, D) 









 Having access to two fluorescent derivatives, it is now possible to begin characterizing these 
compounds in vitro. The first experiment would be to measure the inactivation rate constants of each 
fluorescent derivative 29 and 31 towards GCase. Enzyme inactivation rates of Cerezyme® would be done 
to estimate the binding affinity of 29 and 31 towards recombinant human GCase. Enzyme kinetic studies 
will also be done with GBA2 and GBA3 to evaluate enzyme selectivity of 29 and 31. Next the ability of 
the probes to get into a cell with healthy GCase activity would be measured. In a healthy cell, GCase 
should be concentrated in the lysosomes so overlaying a fluorescent image of probes 29 or 31 with an 
image of cells incubated with LysoTracker® should show fluorescence of both in the same location. 
Lastly the probes should be incubated with high concentrations of a competitive GCase inhibitor to 
compete with 29 and 31 for the GCase binding site. By showing that 29 and 31 do not accumulate in the 
lysosome when GCase is not available it can be assumed that the probes are bound to GCase and not just 
freely floating in the cell or being trapped inside the lysosome by accumulated charge. 
 After these experiments conclude that 29 and 31 have high affinity and specificity towards 
GCase, in vitro studies will be done to assess if these probes are able to cross the blood brain barrier 
(BBB) or if they are substrates of p-glycoprotein or a multidrug resistance transporter.57 In addition, 
experiments performed by Dr. Shusheng Wang in the Phenix lab has indicated the conduritol aziridines 
are transported by myo-inositol transport proteins.  These transport proteins are highly expressed in the 
cells that form the BBB and could transport the aziridine compounds into the brain.  Experiments would 
first incubate cells with the probes 29 and 31 in the presence of myo-inositol as a competition assay.   If 
the aziridines are substrates of these transporters, high concentration of myo-inositol would prevent their 
cellular uptake. Another test using a trans-well assay with a mono-layer of canine kidney cells can be 
used to measure the probes ability to escape the protein pumps that often make small lipophilic 
compounds impermeable to the BBB.81  
 After validation of 29 and 31 as effective molecular probes is complete, these fluorescent 
compounds may act as molecular tools for studying GCase in cell models and animal tissue samples to 
elucidate its role in the progression of PD. If the compounds are shown to suffer from poor binding 
affinity, binding efficiency, GCase selectivity or cell permeability then new derivatives will be developed 





 Although the fluorescent derivatives would act as activity based probes designed for imaging 
GCase in cells, it would be beneficial to know that the fluorinated derivatives also have the ability to 
permeate cells and label GCase in cellulo. This would provide a more accurate indication on how they 
would behave in vivo compared to fluorescent derivatives which contain bulky fluorophores that can 
affect enzyme binding and membrane permeability. Studies can be done to measure inactivation rates of 
GCase in cells by incubating cells with different concentrations of fluorinated derivatives 34 and 39, 
preparing cell lysates from these cells and then measuring residual enzyme activity after incubation. In 
this way it is possible to obtain information on the selectivity of our compounds to GCase over GBA2 and 
GBA3, to obtain information on enzyme inactivation in a more natural setting and to determine how the 
compounds accumulate in a cellular environment.  
 Once a radioactive derivative has been made, fully characterized and tested for quality control, 
animal experiments can commence to study 34 and 39’s biodistribution in a living organism and their 
BBB permeability. If 34 or 39 can permeate the BBB successfully then comparative studies can 
commence to demonstrate the difference in GCase levels in a healthy animal and GCase levels in animal 
with PD. If an image difference can be shown it could validate both GCase as a target in the study of PD 
and the ability of 34 or 39 to detect GCase activity in an in vivo model. These PET probes would be 
valuable molecular tools for elucidating the involvement of GCase in PD, aid in drug design that seek to 
increase GCase levels in PD and Gaucher disease and help unravel the molecular mechanisms of disease 
progression involving GCase. 
Reversible Inhibitors 
 Although there are many examples of irreversible PET imaging agents82 it is possible that an 
irreversible PET tracer that is very potent may suffer from biodistribution issues. Considering there is 
GCase in several tissues in the body besides the brain it is possible that a potent irreversible inhibitor may 
interact and become trapped by GCase outside the brain. Although modifying an irreversible inhibitor to 
improve its biodistribution is possible it may be beneficial to design a reversible inhibitor derivative of 
our compounds. This inhibitor can be designed so that it binds strongly to the enzyme but never becomes 
covalently bound to it. Reversible active site inhibitors of GCase have already been synthesized in the 
literature. They have been shown as well to also possess molecular chaperone abilities, promoting the 
trafficking of mutant and misfolded GCase to the lysosome as a potential therapy of Gaucher disease. 
Once trafficked to the lysosome, a reversible inhibitor may dissociate from the enzyme, allowing the 
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enzyme to act upon its natural substrate glucosylceramide.  In this way a reversible inhibitor may act as a 
suitable PET imaging agent but also act as a potential drug for both Gaucher Disease and potentially PD.  
Conclusions 
  N-octyl conduritol aziridine 7 has been shown to be an extremely potent and selective inhibitor 
of GCase in the literature.46 Recent evidence strongly suggests GCase is involved in the progression of 
PD and could possibly be a therapeutic target. The objective of this thesis work was to develop synthetic 
routes to prepare N-alkylated conduritol aziridine derivatives as potential activity-based probes for 
studying GCase in biological systems. The synthesis of 7 was optimized using MOM protecting groups to 
set in place a synthesis pathway that is efficient, tolerant of the addition of new functional groups and 
finishes with a rapid deprotection step to yield the final compounds. This synthesis pathway was 
implemented to produce two fluorescent derivatives 29 and 31 for the detection of GCase in cell based 
systems. Two fluorinated derivatives 34 and 39 were also produced with the intention of using this 
methodology to prepare radioactive derivatives 42 and 44 for detection of GCase in animal based models 
using PET  imaging. In future work, these activity based probes will be tested for cell permeability, BBB 
permeability, GCase specificity and the ability to detect GCase in biological systems. If successful with 
detecting GCase, whether it be through fluorescent microscopy or PET imaging, these activity based 
probes will be invaluable molecular tools for elucidating GCase’s involvement in the progression of PD, 














All buffers and reagents were obtained from Fisher Scientific or Sigma-Aldrich and used without 
further purification. Synthetic reactions were monitored by TLC using precoated silica gel plates 
(Silicycle 60F254, 0.25mm thickness). Compounds were detected by ultraviolet light (λ = 254nm) 
followed by visualization with ammonium molybdate (10% w/v in 2M H2SO4), permanganate (1% w/v in 
water), or ninhydrin (1.5% w/v solution in butanol), with heating. Flash chromatography was performed 
using Silicyle silica gel (230-400 mesh). NMR spectra were obtained using a Varian Unity Inova 500 
MHz spectrometer dissolving samples in the appropriate deuterated solvents (CDCl3, or CD3OD). 
Chemical shifts were reported in ppm downfield from tetramethylsilane. Low resolution ESI mass 
spectrometry was performed on a Advion Expression CMS Mass Spectrometer. HPLC was done using a 
VP 250/10 Nucleosil 100-5 C18 Nautilus semi-preparative column (100Å, 250 × 10mm, 5 μm).  [18F] 
Fluoride (n.c.a.) was produced on a TR-24 cyclotron (Advanced Cyclotron Systems Inc., Richmond, 
Canada) via the 18O(p,n)18F nuclear reaction.  Depending on the activity required the target was irradiated 
at 18 MeV and the F-18 containing O18 enriched water was transferred and used directly for use in 
synthesis, or the previously emptied target was washed with deionized water followed by transfer to the 




   
1 (2.08 g, 9.46 mmol) was dissolved in 125 mL of DMF. Imidazole (3.86 g, 56.76 mmol) and TBSCl 
(8.56 g, 56.76 mmol) were added and the reaction mixture was heated to 80°C and stirred overnight. The 
next day TBSOTf (5 g, 18.92 mmol) and 2,6-lutidine (2.2 mL, 18.92 mmol) were added and the reaction 
was reacted another 24 hours. The reaction was cooled to room temperature and the solvent was removed 
under vacuum. The crude residue was dissolved in 150 mL of EtOAc and washed with 150 mL of H2O. 
The aqueous layer was extracted 2 x with 100 mL of EtOAc and the organic layers were combined, 
washed with brine, dried with Na2SO4 and filtered. The solvents were removed under vacuum and 
resulting residues was purified using silica gel column chromatography (2% Ethyl ether: Hexanes) to get 
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8 (3.5 g, 55%) as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 4.38 – 4.30 (m, 2H), 4.04 – 3.96 (m, 
2H), 3.84 (d, J = 4.3 Hz, 1H), 3.55 (d, J = 7.7 Hz, 1H), 1.46 (s, 3H), 1.29 (s, 3H), 0.92 – 0.90 (m, 18H), 
0.90 – 0.86 (m, 18H), 0.14 – 0.05 (m, 24H). 13C NMR (126 MHz, CDCl3) δ 113.03, 86.20, 84.37, 82.62, 
82.03, 81.77, 81.72, 81.52, 78.50, 75.02, 49.76, 31.34, 30.98, 30.72, 30.68, 28.56, 23.36, 22.77, 22.76, 
22.71, 4.77, 1.57, 1.50, 1.31, 1.05, 1.00, 0.15, 0.02, -0.00. LRMS (APCI): m/z Calcd for [C33H72O6Si4 + 
Na]+: 699.4298; found: 699.8. 
(±)-(1R,2S,3S,4R,5R,6S)-3,4,5,6-tetrakis((tert-butyldimethylsilyl)oxy)cyclohexane-1,2-diol (9) 
 
8 (48 mg, 0.07 mmol) was mixed in 1.75 mL of CH2Cl2 and cooled to 0°C. Freshly made 4:4:1 TFA: 
CH2Cl2: H2O (0.175 mL) was added to this mixture and the reaction was stirred vigorously at 0°C for 1 
hour. The reaction was then quenched with saturated NaHCO3 at the same temperature and partitioned 
between 10 mL of EtOAc and 10 mL of H2O. The aqueous layer was extracted 2 x with 10 mL of EtOAc 
and the organic layers were combined, washed with brine, dried with Na2SO4 and filtered. The solvents 
were removed under vacuum and resulting residues was purified using silica gel column chromatography 
(2%→5% EtOAc: Hexanes) to get 9 (28 mg, 63%) as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 4.02 
(dd, J = 7.4, 5.8 Hz, 2H), 3.81-3.70 (m, 2H), 3.26 (dd, J = 12.1, 3.5 Hz, 1H), 2.71 (dd, J = 11.4, 3.2 Hz, 
1H), 0.96 – 0.90 (m, 18H), 0.90-0.84 (m, 18H), 0.27 – 0.04 (m, 24H). LRMS (ESI -ve): m/z Calcd for 
[C30H68O6Si4 - H]




1 (1 g, 4.54 mmol) was added to 26 mL of dry pyridine with DMAP (55 mg, 0.454 mmol). BzCl (4.22 
mL, 36.32 mmol) was added to the mixture and the reaction occurred for 24 hours at room temperature. 
The mixture was diluted with 100 mL of EtOAc and washed with 100 mL of a 5% CuSO4 aqueous 
solution. The aqueous layer was extracted 2 x with 50mL of EtOAc and the organic layers were 
51 
 
combined, washed with brine, dried with Na2SO4 and filtered. The solvents were removed under vacuum 
and the product was purified by silica gel column chromatography (8:1 Hexanes: EtOAc) to get 11 (2.74 
g, 95 %) as a white powder. NMR consistent with that published in the literature.83  
(±)-(1S,2R,3R,4S,5R,6S)-5,6-dihydroxycyclohexane-1,2,3,4-tetrayl tetrabenzoate (12) 
 
11 (13 g, 20.42 mmol) was dissolved in 80% AcOH(aq) and refluxed for 4 hours. Solvent was removed 
under vacuum. The product was purified by silica gel column chromatography (1:2 → 1:1 EtOAc: 
Hexanes) to get 12 (11.56 g, 95 %) as a white powder. 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.9 Hz, 
2H), 7.94 (d, J = 7.9 Hz, 2H), 7.88 – 7.79 (m, 2H), 7.53 – 7.46 (m, 2H), 7.37 – 7.30 (m, 4H), 7.31 – 7.22 
(m, 4H), 6.34 (dd, J = 10.9, 9.2 Hz, 1H), 5.97 – 5.83 (m, 2H), 5.47 (dd, J = 10.4, 2.3 Hz, 1H), 4.62 (d, J = 
2.3 Hz, 1H), 4.14 (dd, J = 8.8, 1.0 Hz, 1H), 3.43 (br s, 1H). 13C NMR (126 MHz, CDCl3) δ 167.17, 
165.89, 165.85, 165.81, 133.56, 133.48, 133.29, 133.26, 130.03, 129.84, 129.78, 129.14, 129.10, 129.05, 
128.94, 128.56, 128.46, 128.40, 73.85, 72.44, 71.16, 71.05, 70.70, 70.17. LRMS (ESI): m/z Calcd for 
[C34H28O10 + Na]
+: 619.1575; found: 619.7. 
(±)-(1R,2S,3R,4S,5S,6R)-5-azido-6-((methylsulfonyl)oxy)cyclohexane-1,2,3,4-tetrayl tetrabenzoate 
(13) 
             
12 (5 g, 8.39 mmol) was dissolved in 24 mL of pyridine and cooled to 0°C. MsCl (3.25 mL, 41.94 mmol) 
was added dropwise and the reaction was allowed to warm to room temperature overnight. The mixture 
was diluted with 100 mL of EtOAc and washed with 100 mL of an 5% CuSO4 aqueous solution. The 
aqueous layer was extracted 2 x with 50mL of EtOAc and the organic layers were combined, washed with 
brine, dried with Na2SO4 and filtered. The solvents were removed under vacuum and the crude was 
filtered through a pad of silica gel using 1:1 EtOAc: Hexanes to quantitatively get 6 grams of essentially 
pure dimesylate 13a 1H NMR (500 MHz, CDCl3) δ 7.99 (dd, J = 17.4, 7.3 Hz, 4H), 7.83 (d, J = 8.0 Hz, 
4H), 7.56 – 7.48 (m, 2H), 7.47 – 7.34 (m, 6H), 7.34 – 7.27 (m, 4H), 6.22 (dd, J = 11.6, 8.7 Hz, 1H), 6.12 
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(dd, J = 11.5, 8.7 Hz, 1H), 5.95 (dd, J = 11.5, 8.5 Hz, 1H), 5.74 – 5.59 (m, J = 5.4, 2.6 Hz, 2H), 5.32 
(ddd, J = 11.2, 7.0, 2.9 Hz, 1H), 3.24 (s, 3H), 2.99 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.53, 165.48, 
165.39, 165.25, 133.94, 133.86, 133.62, 133.55, 130.14, 129.99, 129.93, 129.84, 128.72, 128.62, 128.50, 
128.42, 128.38, 77.25, 74.34, 70.49, 69.41, 69.28, 69.13, 39.42, 38.99. The crude dimesylate (1 g, 1.328 
mmol) was dissolved in 7 mL of DMF and NaN3 (432 mg, 6.64 mmol) was added. The reaction was 
heated to 75°C and reacted for 48 hours. The mixture was cooled to room temperature and diluted with 
100 mL of EtOAc and 100 mL of H2O. The aqueous layer was extracted 2 times with 50 mL of EtOAc 
and the organic layers were combined, washed with brine, dried with Na2SO4 and filtered. The solvents 
were removed under vacuum and the crude was not shown to contain 13. 
 (±)-1,2-O-benzylidene-myo-inositol (15) 
 
Myo-inositol (15 g, 83.33 mmol) and p-toluene sulfonic acid (700 mg, 3.68 mmol) were dissolved in 160 
mL of DMF. In a second flask dimethoxy toluene (20 mL, 133.25 mmol) was dissolved in 48 mL of 
DMF. This solution was added to the reaction vessel with stirring and the mixture was heated to 120°C 
for 1 h. Anhydrous sodium carbonate (1170 mg, 11.14 mmol) was then added to the reaction mixture and 
the solvent was removed under vacuum. The resulting residue was purified using silica gel column 
chromatography (1:0 → 2:1, CH2Cl2:MeOH) to get 15 (15.57 g, 70%) as a white powder. NMR 










phenylhexahydrobenzo[d][1,3]dioxole (16)     
 
15 (15 g, 55.9 mmol) was dissolved in 45 mL of DMF and 66.2 mL of DIPEA. MOMCl (21 mL, 276.5 
mmol) was added slowly at room temperature and the mixture was heated to 65°C overnight. The reaction 
was allowed to cool to room temperature and was quenched with 200 mL of water. The aqueous layer 
was extracted with 3 times 200 mL of EtOAc. The organic portions were collected and washed with 0.1 
M HCl until neutralized and washed with brine. The organic layer was dried with sodium sulphate, 
filtered and concentrated under vacuum. The residue was purified with silica gel column chromatography 
(1:1, EtOAc: Hexanes) to get 16 as a diastereotopic mixture (dr, 50:50), (24 g, 95%) in the form of a 
colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.61 – 7.55 (m, 2H), 7.51 – 7.43 (m, 2H), 7.41 – 7.33 (m, 
6H), 6.23 (s, 1H), 5.86 (s, 1H), 4.90 – 4.75 (m, 16H), 4.57 – 4.46 (m, 2H), 4.38 – 4.23 (m, 2H), 4.17 – 
4.07 (m, 2H), 4.07 – 3.91 (m, 4H), 3.72 – 3.57 (m, 2H), 3.50 – 3.39 (m, 18H), 3.38 – 3.35 (m, 6H). 13C 
NMR (126 MHz, CDCl3) δ 129.55, 129.13, 128.37, 127.23, 126.25, 104.61, 103.59, 97.51, 97.15, 96.59, 
79.47, 78.90, 78.71, 78.33, 77.92, 77.51, 76.45, 75.79, 75.53, 74.82, 56.19, 55.83.  LRMS (ESI): m/z 
Calcd for [C21H32O10 + Na]
+: 467.1888; found: 467.6. 
(±)-(1R,2S,3S,4R,5R,6S)-3,4,5,6-tetrakis(methoxymethoxy)cyclohexane-1,2-diol (17) 
 
16 (23 g, 33.75 mmol) was dissolved in 50 mL of EtOAc. 3 grams of 10 wt % Pd/C was added and the 
reaction was stirred under hydrogen atmosphere (1 atm) overnight. The mixture was filtered through a 
small portion of celite followed by silica gel to provide essentially pure 17 (11.4 g, 95%) after 
concentration under vacuum as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 4.93 – 4.68 (m, 8H), 4.41 
– 4.37 (m, 1H), 4.26 – 4.19 (m, 1H), 3.98 (dd, J = 14.9, 9.7 Hz, 1H), 3.67 (dd, J = 14.6, 9.3 Hz, 1H), 3.55 
– 3.49 (m, 1H), 3.48 – 3.40 (m, 12H), 2.88 – 2.80 (m, 1H).  13C NMR (126 MHz, CDCl3) δ 98.96, 98.51, 
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98.33, 96.68, 84.52, 78.90, 77.34, 70.81, 70.38, 56.31, 56.06, 55.78. LRMS (ESI): m/z Calcd for 
[C14H28O10 + Na]




17 (600 mg, 1.68 mmol) was dissolved in 4 mL of pyridine and cooled to 0°C. Mesyl chloride (0.65 mL, 
8.42 mmol) was added dropwise and the reaction was allowed to warm to room temperature and react 
overnight. The mixture was separated between 50 mL 5% CuSO4 solution and 50 mL of EtOAc. The 
aqueous layer was extracted 2 times with 50 mL of EtOAc and the organic layers were washed once with 
water and once with brine. The organic layer was dried with sodium sulfate, filtered and concentrated 
under vacuum to get 18 (815 mg, 95%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 5.30 – 5.21 (m, 
1H), 4.94 – 4.69 (m, 8H), 4.55 (dt, J = 10.1, 2.7 Hz, 1H), 3.93 (dd, J = 10.9, 8.6 Hz, 1H), 3.86 (dd, J = 
11.1, 8.7 Hz, 1H), 3.69 (dd, J = 6.5, 3.5 Hz, 1H), 3.51 (dd, J = 10.9, 8.2 Hz, 1H), 3.48 – 3.37 (m, 12H), 
3.22 – 3.17 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 98.85, 98.75, 98.65, 98.56, 96.42, 79.25, 78.89, 
76.42 , 75.72, 73.35,56.65 , 56.63, 56.41, 39.45,  39.19. LRMS (ESI): m/z Calcd for [C16H32O14S2 + Na]
+: 
535.1126; found: 535.0. 
(±)-(1R,2S,3R,4R,5S,6S)-2,3,4,5-tetrakis(methoxymethoxy)-7-azabicyclo[4.1.0]heptane (19) 
 
18 (11 g, 21.48 mmol) and NaN3 (1.54 g, 23.63 mmol) was dissolved in 185 mL of DMF and heated at 
75°C for 2 days. The mixture was cooled to room temperature and partitioned between 400 mL of water 
and 400 mL of EtOAc. After extracting 3 times with 400 mL EtOAc the organic layers were combined 
and washed with brine then dried with sodium sulphate. The solvent was filtered and concentrated under 
vacuum to get the monoazide compound in a crude mixture as a colourless oil. To this was added 
triethylamine (6.3 mL, 45.11 mmol) and Ph3P (8.45 g, 32.22 mmol) which were then dissolved in 130 mL 
of THF and allowed to react for 30 minutes at room temperature. 13 mL of water was added and the 
reaction mixture was heated to reflux overnight. The reaction was quenched with 400 mL of water and 
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extracted 3 times with 400 mL of EtOAc. The organic layers were combined and washed with brine, dried 
with sodium sulphate, filtered and concentrated under vacuum. The crude residue was purified using 
silica gel column chromatography (100% EtOAc) to get 19 (4.14 g, 58% over 2 steps) as a light yellow 
oil. 1H NMR (500 MHz, CDCl3) δ 4.89 – 4.70 (m, 8H), 3.89 – 3.73 (m, 2H), 3.56 (dd, J = 9.4 Hz, J = 9.4 
Hz 1H), 3.42 (s, 6H), 3.38 (s, 6H), 3.37 – 3.31 (m, 1H), 2.70 – 2.57 (m, 1H), 2.48 – 2.34 (m, 1H), 0.79 (br 
s, 1H). 13C NMR (126 MHz, CDCl3) δ 98.38, 97.95, 97.67, 97.16, 80.26, 79.90, 78.78, 75.87, 56.25, 
56.13, 55.99, 55.61, 34.94, 33.72. LRMS (ESI): m/z Calcd for [C14H27 NO8 + Na]
+: 360.162888; found: 
360.3. HRMS (TOF ESI); found: 360.1634. 
(±)-(1R,2S,3R,4R,5S,6S)-2,3,4,5-tetrakis(methoxymethoxy)-7-octyl-7-azabicyclo[4.1.0]heptane (20) 
 
19 (200 mg, 0.593 mmol) was dissolved in 6.2 mL of acetonitrile. DIPEA (0.31 mL, 1.778 mmol), and 
iodo octane (0.32 mL, 1.778 mmol) were added and the reaction was refluxed for 2 days. The mixture 
was diluted with 100 mL of EtOAc and 100 mL H2O. The aqueous layer was extracted with 75 mL of 
EtOAc 2 times and the organic layers were combined, washed with brine, dried with Na2SO4 and filtered. 
The solvents were removed under vacuum and the crude was purified using silica gel chromatography 
(1:2 → 1:1 EtOAc: Hexanes) to get 20 (146 mg, 55%) as a colourless oil.  1H NMR (500 MHz, CDCl3) δ 
4.91 – 4.68 (m, 8H), 3.81 – 3.74 (m, 2H), 3.54 (dd, J = 6.8, 3.6 Hz, 1H), 3.48 – 3.39 (m, 12H), 3.39 – 
3.31 (m, 2H), 2.70 – 2.61 (m, 1H), 1.96 (dd, J = 5.7, 3.4 Hz, 1H), 1.91 – 1.81 (m, 1H), 1.66 (t, J = 5.5 Hz, 
1H), 1.63 – 1.48 (m, 2H), 1.36 – 1.21 (m, 9H), 0.88 (dd, J = 9.4, 4.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 98.50, 98.09, 97.64, 97.18, 80.34, 79.75, 79.00, 61.35, 56.23, 55.93, 55.58, 43.44, 42.28, 31.98, 












20 (40 mg, 0.089 mmol) was dissolved in 0.65 mL of acetonitrile and cooled to 0°C. TMSBr (233 μg, 
1.78 mmol) was added slowly to the mixture and this was stirred for 40 minutes at 0°C. The reaction was 
quenched with 2 mL of saturated sodium bicarbonate while stirring vigorously and allowed to warm to 
room temperature. The volatiles were removed under vacuum. The resulting solids were dissolved in 1:1 
MeOH:CHCl3, filtered and the solvents were again removed under vacuum. This crude mixture was 
purified using silica gel column chromatography (1:6, MeOH:CHCl3) and lyophilized to get 7 (15 mg, 
62%). 1H NMR (500 MHz, CD3OD) δ 3.66 (dd, J = 8.4, 3.6 Hz, 1H), 3.59 (d, J = 8.1 Hz, 1H), 3.23 – 3.15 
(m, 1H), 3.02 (dd, J = 10.3, 8.2 Hz, 1H), 2.38 – 2.29 (m, 1H), 2.17 – 2.07 (m, 1H), 1.94 – 1.86 (m, 1H), 
1.59 (d, J = 6.8 Hz, 1H), 1.58 – 1.49 (m, 2H), 1.36 – 1.20 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). 13C NMR 
(126 MHz, CD3OD) δ 77.84, 74.06, 73.42, 73.12, 62.08, 49.85, 45.84, 45.42, 33.04, 30.73, 30.40, 28.42, 
23.74, 14.45. LRMS (ESI): m/z Calcd for [C14H27 NO4 + H]
+: 274.201285; found: 274.5. HRMS (TOF 





19 (250 mg, 0.741 mmol) was dissolved in 7.5 mL of acetonitrile. DIPEA (0.38 mL, 2.222 mmol), NaI 
(333 mg, 2.222 mmol) and 21a (441 mg, 1.111 mmol) were added and the reaction was refluxed for 2 
days. The mixture was diluted with 100 mL of EtOAc and 100 mL H2O. The aqueous layer was extracted 
with 75 mL of EtOAc 2 times and the organic layers were combined, washed with brine, dried with 
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Na2SO4 and filtered. The solvents were removed under vacuum and the crude was purified using silica gel 
chromatography (1:1 → 2:1 EtOAc: Hexanes) to get 21 (244 mg, 55%) as a red solid. 1H NMR (500 
MHz, CDCl3) δ 6.05 (s, 2H), 4.87 – 4.72 (m, 8H), 3.77 (dd, J = 8.7, 3.4 Hz, 1H), 3.73 (d, J = 8.3 Hz, 1H), 
3.57 – 3.47 (m, 1H), 3.46 – 3.37 (m, 12H), 3.37 – 3.32 (m, 1H), 3.00 – 2.89 (m, 2H), 2.74 – 2.59 (m, 1H), 
2.51 (s, 6H), 2.41 (s, 6H), 1.99 – 1.85 (m, 2H), 1.68 – 1.58 (m, 7H). 13C NMR (126 MHz, CDCl3) δ 
153.87, 146.60, 140.46, 131.54, 121.70, 98.40, 98.08, 97.71, 97.19, 80.20, 79.80, 78.91, 76.69, 60.58, 
56.28, 56.18, 55.95, 55.59, 43.46, 42.21, 31.97, 29.45, 28.50, 28.13, 16.49, 14.59.  LRMS (ESI): m/z 
Calcd for [C32H50 BF2N3O8 + Na]




9-chloroacridine (150 mg, 0.702 mmol) and potassium iodide (1165 mg, 7.020 mmol) was dissolved in 15 
mL of acetone and refluxed overnight in the dark. The resulting slurry was dissolved in 100 mL of EtOAc 
and 100 mL of water. The organic layer was collected and the aqueous layer was extracted 2 more times 
with 100 mL of EtOAc. The organic layers were combined, washed with brine, dried with sodium 
sulphate and concentrated under vacuum. The resulting solid 28a was used directly in the next step. Some 
of the isolated 28a (109 mg, 0.358 mmol) and compound 32 (62 mg, 0.149 mmol) was dissolved in a 
degassed solution of 1:1 THF:triethylamine (2 mL). To this solution was added tetrakis (3.5 mg, 0.003 
mmol) and CuI (5.7 mg, 0.03 mmol). The solution was refluxed for 1.5 hours and then cooled to room 
temperature. The mixture was separated between 20 mL of EtOAc and 20 mL of water. The aqueous 
layer was extracted 3 times with 20 mL EtOAc. The organic layers were combined, washed with brine, 
dried with sodium sulphate, filtered and concentrated under vacuum. The resulting residue was purified 
using silica gel chromatography (2:1 to 5:1 EtOAc:Hexanes) to get 28 (60 mg, 68%) as an orange solid. 
1H NMR (500 MHz, CDCl3) δ 8.46 (d, J = 8.5 Hz, 2H), 8.21 (d, J = 8.7 Hz, 2H), 7.78 (dd, J = 7.5, 7.5 Hz, 
2H), 7.59 (dd, J = 7.4, 7.4 Hz, 2H), 4.86 – 4.63 (m, 8H), 3.81 – 3.75 (m, 2H), 3.60 – 3.52 (m, 1H), 3.44 – 
3.30 (m, 12H), 2.89 – 2.70 (m, 3H), 2.14 – 1.98 (m, 2H), 1.98 – 1.91 (m, 2H), 1.91 – 1.80 (m, 2H), 1.71 
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(d, J = 6.0 Hz, 1H). 1.29 - 1.21 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 148.55, 130.22, 129.78, 126.81, 
126.23, 98.31, 97.93, 97.57, 97.10, 80.16, 79.70, 78.76, 76.64, 60.31, 56.16, 56.02, 55.78, 55.43, 43.53, 
42.12, 29.06, 26.60, 20.30. LRMS (ESI): m/z Calcd for [C33H42 N2O8 + H]




28 (50 mg, 0.084 mmol) was dissolved in 0.65 mL of acetonitrile and cooled to 0°C. TMSBr (220 μL, 
1.68) mmol) was added slowly to the mixture and this was stirred for 40 minutes at 0°C. The reaction was 
quenched with 2 mL of saturated sodium bicarbonate while stirring vigorously and allowed to warm to 
room temperature. The volatiles were removed under vacuum. The resulting solids were dissolved in 1:1 
MeOH: CHCl3, filtered and the solvents were again removed under vacuum. This crude mixture was 
purified using silica gel column chromatography (1:6 → 1:5 MeOH: EtOAc) and lyophilized to get 29 
(15 mg, 62%). 1H NMR (500 MHz, CD3OD) δ 8.44 (d, J = 8.2 Hz, 2H), 8.12 (d, J = 8.3 Hz, 2H), 7.86 
(dd, J = 7.5, 7.5 Hz, 2H), 7.67 (dd, J = 7.2, 7.2 Hz, 2H), 3.79 (dd, J = 8.4, 3.1 Hz, 1H), 3.72 (d, J = 8.0 
Hz, 1H), 3.16 (dd, J = 9.3, 9.3 Hz, 1H), 2.97 – 2.75 (m, 2H), 2.52 (dd, J = 12.9, 6.3 Hz, 1H), 2.38 (dd, J = 
10.3, 5.8 Hz, 1H), 2.12 – 1.98 (m, 1H), 1.98 – 1.84 (m, 4H), 1.78 (d, J = 6.2 Hz, 1H). 13C NMR (126 
MHz, CD3OD) δ 149.05, 132.15, 129.35, 127.81, 127.76, 109.93, 77.55, 77.53, 77.48, 76.15, 74.10, 
73.30, 72.90, 61.18, 45.83, 45.43, 30.03, 27.53, 20.81. LRMS (ESI): m/z Calcd for [C25H26 N2O4 + H]
+: 










32 (54 mg, 0.130 mmol) and 30a (95 mg, 0.155 mmol) were added to 4 mL of THF spiked with 0.1 mL 
of TEA. To this mixture was added Pd(PPh3)4 (3 mg, 0.0026 mmol) and CuI (5 mg, 0.026 mmol). This 
mixture was reacted for 2 days at room temperature. The mixture was filtered and the mixture was diluted 
with 50 mL of EtOAc and 50 mL H2O. The aqueous layer was extracted with 25 mL of EtOAc 2 times 
and the organic layers were combined, washed with brine, dried with Na2SO4 and filtered. The solvents 
were removed under vacuum and the crude was purified using silica gel chromatography (1:2 EtOAc: 
Hexanes) to get 30 (36 mg, 31%) as a clear slightly orange oil. 1H NMR (500 MHz, CDCl3) δ 8.10 – 7.94 
(m, 1H), 7.84 – 7.56 (m, 1H), 7.49 (dd, J = 24.5, 7.8 Hz, 1H), 7.14 (s, 2H), 6.87 (d, J = 14.0 Hz, 1H), 4.92 
– 4.67 (m, 8H), 3.92 – 3.87 (m, 1H), 3.74 (dd, J = 29.4, 8.2 Hz, 2H), 3.53 (dd, J = 19.9, 11.1 Hz, 1H), 
3.48 – 3.38 (m, 12H), 3.37 – 3.32 (m, 1H), 2.81 – 2.60 (m, 1H), 2.58 – 2.40 (m, 2H), 2.37 (s, 4H), 2.02 – 
1.87 (m, 2H), 1.85 – 1.52 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 167.95, 167.83, 150.15, 149.73, 
149.61, 148.54, 138.83, 128.95, 128.38, 127.24, 126.05, 123.88, 122.76, 117.39, 112.78, 98.35, 97.97, 
97.62, 97.13, 93.82, 80.47, 80.18, 79.73, 78.99, 78.85, 76.66, 60.36, 56.19, 56.06, 55.84, 55.72, 55.49, 
55.45, 43.47, 42.17, 29.72, 28.83, 26.28, 20.64, 19.47. LRMS (ESI): m/z Calcd for [C44H47Cl2NO15 + H]
+: 











30 (36 mg, 0.04 mmol) was dissolved in 0.5 mL of acetonitrile and cooled to 0°C. TMSBr (105 μL, 0.80 
mmol) was added slowly to the mixture and this was stirred for 40 minutes at 0°C. The reaction was 
quenched with 1 mL of saturated sodium bicarbonate while stirring vigorously and allowed to warm to 
room temperature. The volatiles were removed under vacuum. 1 mL of MeOH and 15 mg of K2CO3 were 
added and the slurry was stirred for 1 hour at room temperature. The resulting solution was dissolved in 
1:1 MeOH: CHCl3, filtered and the solvents were again removed under vacuum. This crude mixture was 
purified using silica gel column chromatography (10% → 15% MeOH: CHCl3) and lyophilized to get 29 
(23 mg, 90%) as an orange solid. 1H NMR (500 MHz, CD3OD) δ 8.19 – 7.98 (m, 1H), 7.67 – 7.55 (m, 
1H), 7.27 – 7.13 (m, 1H), 7.11 (d, J = 4.3 Hz, 2H), 6.58 (s, 2H), 3.72 (dd, J = 8.4, 2.9 Hz, 1H), 3.66 (dd, J 
= 31.7, 7.9 Hz, 1H), 3.07 (dd, J = 18.2, 8.3 Hz, 1H), 2.53 (t, J = 6.4 Hz, 1H), 2.50 – 2.41 (m, 1H), 2.35 – 
2.10 (m, 1H), 2.06 – 1.96 (m, 1H), 1.88 – 1.62 (m, 7H). 13C NMR (126 MHz, CD3OD) δ 180.48, 176.14, 
158.78, 155.18, 133.21, 130.83, 129.67, 129.59, 129.17, 129.13, 126.91, 126.77, 112.75, 106.37, 104.78, 
93.79, 80.77, 77.73, 77.64, 74.15, 74.06, 73.40, 72.97, 61.43, 61.35, 45.93, 45.48, 29.82, 27.52, 27.42, 
24.21, 20.05. LRMS (ESI -ve): m/z Calcd for [C32H27Cl2NO9 - H]











19 (700 mg, 2.075 mmol), 6-iodo-1-hexyne (0.82 mL, 6.224 mmol) and DIPEA (1.08 mL, 6.224 mmol) 
were dissolved in 22 mL of acetonitrile and heated to reflux for 2 days. The reaction was allowed to cool 
to room temperature and the solvent was removed under vacuum. The crude reaction mixture was 
partitioned between 200 mL of EtOAc and 200 mL of water. The aqueous layer was extracted 2 more 
times with 100 mL of EtOAc. The organic layers were combined and washed with brine, dried with 
sodium sulphate, filtered and concentrated under vacuum. The mixture was then purified using silica gel 
chromatography (1:1 EtOAc:Hexanes) to get 32 (228 mg, 30%) as a colourless oil. 1H NMR (500 MHz, 
CDCl3) δ 4.87 – 4.70 (m, 8H), 3.75 (dd, J = 14.0, 5.6 Hz, 2H), 3.51 (dd, J = 9.5, 9.4 Hz, 1H), 3.42 (s, 6H), 
3.39 (s, 6H), 3.36 – 3.28 (m, 1H), 2.69 – 2.57 (m, 1H), 2.25 – 2.15 (m, 2H), 1.99 – 1.84 (m, 3H), 1.73 – 
1.50 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 98.46, 98.06, 97.70 , 97.19 , 84.50, 80.32 , 79.76 , 78.89 , 
76.81, 68.52, 60.44, 56.29, 56.15 , 55.94, 55.60 , 43.53, 42.21, 28.67, 26.25, 18.49.  LRMS (ESI): m/z 
Calcd for [C20H35NO8 + Na]
















32 (75.06 mg, 0.18 mmol), triethylamine (0.1 mL, 0.72 mmol), CuI (8 mg, 0.04 mmol) and tetrakis (4 mg, 
0.034 mmol) were dissolved in 3 mL of acetonitrile. To this was added 4-fluoroiodobenzene (22 μL, 
0.198 mmol) and the reaction was refluxed for 20 minutes. The reaction was cooled and partitioned 
between 20 mL of water and 20 mL of EtOAc. The aqueous phase was extracted 2 times with 20 mL of 
EtOAc and the organic layers were combined. The organic portion was washed with brine, dried with 
sodium sulphate, filtered and concentrated under vacuum. After silica gel column chromatography (1:2 
EtOAc:Hexanes ) 33 (90 mg, 95%) was isolated as a colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.35 
(dd, J = 5.6, 8.4 Hz, 2H), 6.96 (dd, J = 8.7, 8.7 Hz, 2H), 4.86 – 4.72 (m, 8H), 3.77 (dd, J = 5.3, 10.1 Hz, 
2H), 3.53 (dd, J = 9.5, 9.5 Hz, 1H), 3.46 – 3.38 (m, J = 7.4, 2.8 Hz, 12H), 3.38 – 3.31 (m, 1H), 2.69 (dd, J 
= 11.4, 6.5 Hz, 1H), 2.41 (t, J = 6.0 Hz, 2H), 2.02 – 1.89 (m, 2H), 1.83 – 1.64 (m, 5H). 13C NMR (126 
MHz, CDCl3) δ 163.09, 161.10, 133.42, 133.35, 120.11, 115.52, 115.35, 98.42, 98.03, 97.65, 97.17, 
89.75, 80.27, 79.73, 78.89, 76.77, 60.54, 56.25, 56.12, 55.88, 55.54, 43.51, 42.23, 28.89, 26.53, 19.42.  
LRMS (ESI): m/z Calcd for [C26H38FNO8 + H]













33 (50 mg, 0.098 mmol) was dissolved in 1 mL of acetonitrile and cooled to 0°C. TMSBr (256 μL, 1.960 
mmol) was added slowly to the mixture and this was stirred for 40 minutes at 0°C. The reaction was 
quenched with 2 mL of saturated sodium bicarbonate while stirring vigorously at 0°C and allowed to 
warm to room temperature. The solvent was removed under vacuum. The resulting solids were dissolved 
in 1:1 MeOH: CHCl3, filtered and the solvents were again removed under vacuum. This crude mixture 
was purified using silica gel column chromatography (1:6, MeOH: CHCl3) and lyophilized to get 34 (16 
mg, 49%) as an off white solid. 1H NMR (500 MHz, CD3OD) δ 7.38 (dd, J = 5.5, 8.6 Hz, 2H), 7.03 (dd, J 
= 8.8, 8.8 Hz, 2H), 3.70 (dd, J = 8.4, 3.5 Hz, 1H), 3.65 (d, J = 8.1 Hz, 1H), 3.24 (dd, J = 8.7, 10.1 Hz, 
1H), 3.06 (dd, J = 8.2, 10.3 Hz, 1H), 2.49 – 2.36 (m, 3H), 2.30 – 2.19 (m, 1H), 1.96 (dd, J = 6.0, 3.7 Hz, 
1H), 1.81 – 1.70 (m, 2H), 1.71 – 1.61 (m, 3H). 13C NMR (126 MHz, CD3OD) δ 134.49, 134.42, 116.40, 
116.23, 90.45, 80.65, 77.88, 74.08, 73.43, 73.13, 61.39, 45.89, 45.41, 29.79, 27.59, 19.86. LRMS (ESI): 
m/z Calcd for [C18H22FNO4 + H]
+: 336.160563; found: 336.6. HRMS (TOF ESI); found: 336.1615. 
Or 
35 (21.7 mg, 0.09 mmol), triethylamine (50 μg, 0.36 mmol), CuI (4 mg, 0.02 mmol) and tetrakis (2 mg, 
0.0017 mmol) were dissolved in 1.5 mL of an acetonitrile water mixture (1:1). To this was added 4-
fluoroiodobenzene (11 μL, 0.099 mmol) and the reaction was heated at 90°C for 20 minutes. The reaction 
was cooled and partitioned between 10 mL of water and 10 mL of EtOAc. The aqueous phase was 
extracted 2 times with 10 mL of EtOAc and the organic layers were combined. The organic portion was 
washed with brine, dried with sodium sulphate, filtered and concentrated under vacuum. After silica gel 
column chromatography (1:6, MeOH:CHCl3) 34 (27 mg, 90%) was isolated as a white solid and matched 






32 (200 mg, 0.480 mmol) was dissolved in 5 mL of acetonitrile and cooled to 0°C. TMSBr (1.26 mL, 
9.592 mmol) was added slowly to the mixture and this was stirred for 40 minutes at 0°C. The reaction 
was quenched with 10 mL of saturated sodium bicarbonate while stirring vigorously at 0°C and allowed 
to warm to room temperature. The solvent was removed under vacuum. The resulting solids were 
dissolved in 1:1 MeOH:CHCl3, filtered and the solvents were again removed under vacuum. This crude 
mixture was purified using silica gel column chromatography (6:1 to 5:1, EtOAc: MeOH) and lyophilized 
to get 35 (110 mg, 95%) as an white solid. 1H NMR (500 MHz, CD3OD) δ 3.75 (dd, J = 8.3, 3.1 Hz, 1H), 
3.65 (d, J = 8.1 Hz, 1H), 3.29 – 3.22 (m, 1H), 3.11 (dd, J = 8.7, 9.9 Hz, 1H), 2.40 (dd, J = 11.7, 7.0 Hz, 
1H), 2.29 – 2.13 (m, 4H), 2.03 – 1.93 (m, 1H), 1.75 – 1.64 (m, 3H), 1.64 – 1.54 (m, 2H). 13C NMR (126 
MHz, CD3OD) δ 84.82, 77.52, 74.03, 73.29, 72.89, 69.65, 61.21, 45.77, 45.37, 29.55, 27.38, 18.95. 
LRMS (ESI): m/z Calcd for [C12H19NO4 + Na]




19 (700 mg, 2.075 mmol), 9-bromo-1-nonanol (1.39 g, 6.225 mmol), NaI (933 mg, 6.225 mmol) and 
DIPEA (1.08 mL, 6.225 mmol) were dissolved in 21 mL of acetonitrile and refluxed for 2 days. The 
reaction was allowed to cool to room temperature and the solvent was removed under vacuum. The crude 
reaction mixture was partitioned between 200 mL of EtOAc and 200 mL of water and extracted 2 more 
times with 200 mL of EtOAc. The organic layers were combined and washed with brine, dried with 
sodium sulphate, filtered and concentrated under vacuum. The mixture was then purified using silica gel 
chromatography (2:1 to 5:1 EtOAc: Hexanes) to get 36 (350 mg, 35%) as a colourless oil. 1H NMR (500 
MHz, CDCl3) δ 4.92 – 4.72 (m, 8H), 3.77 (dd, J = 14.6, 5.7 Hz, 2H), 3.62 (dd, J = 6.6, 6.6 Hz, 2H), 3.53 
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(dd, J = 9.5, 9.5 Hz, 1H), 3.48 – 3.38 (m, 12H), 3.39 – 3.31 (m, 1H), 2.65 (dd, J = 7.6, 16.7 Hz, 1H), 2.00 
– 1.91 (m, 1H), 1.92 – 1.82 (m, 1H), 1.66 (d, J = 6.0 Hz, 1H), 1.63 – 1.50 (m, 4H), 1.42 – 1.20 (m, 11H). 
13C NMR (126 MHz, CDCl3) δ 98.36, 97.98, 97.52,97.06, 80.21, 79.62, 78.88, 76.76, 62.91, 61.18, 56.19, 
56.07, 55.84, 55.49, 43.35,42.18, 32.81, 29.54, 29.49, 29.37, 27.28, 25.76. LRMS (ESI): m/z Calcd for 
[C23H45NO9 + Na]




36 (130 mg, 0.27 mmol) was dissolved with triethylamine (57 μL, 0.41 mmol) in dichloromethane. The 
reaction mixture was cooled to 0oC and mesyl chloride (31 μL, 0.41 mmol) was added dropwise while 
vigorously stirring. The mixture was stirred on ice for 45 minutes before it was quenched with 3 mL of 
saturated NH4Cl. The mixture was extracted 3 times with 5 mL of dichloromethane. The organic portions 
were washed with brine, dried with sodium sulphate, filtered and concentrated under vacuum. The 
resulting residue was purified on silica gel chromatography (1:1 to 2:1 EtOAc: Hexanes) to get 37 (105 
mg, 70%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 4.88 – 4.68 (m, 8H), 4.20 (dd, J = 6.6, 6.6 Hz, 
2H), 3.78 – 3.69 (m, 2H), 3.53 – 3.48 (m, 1H), 3.46 – 3.35 (m, 12H), 3.36 – 3.29 (m, 1H), 2.99 (s, 3H), 
2.68 – 2.57 (m, 1H), 1.97 – 1.91 (m, 1H), 1.89 – 1.78 (m, 1H), 1.76 – 1.67 (m, 2H), 1.63 (d, J = 6.1 Hz, 
1H), 1.61 – 1.46 (m, 2H), 1.41 – 1.21 (m, 10H). 13C NMR (126 MHz, CDCl3) δ 98.43, 98.06, 97.58, 
97.14, 80.27, 79.69, 78.94, 76.82, 70.29, 61.20, 56.25, 56.14, 55.90, 55.55, 43.41, 42.23, 37.45, 29.61, 













37 (45 mg, 0.081 mmol) was dissolved in 1 mL of acetonitrile. To this solution was added TEAF (24 mg, 
0.162 mmol) and the mixture was refluxed in a preheated bath for 30 minutes. The reaction was cooled 
and separated between 30 mL of EtOAc and 30 mL of water. The water phase was extracted 2 more times 
with 15 mL of EtOAc and the organic layers were combined. The organic layers were washed with brine, 
dried with sodium sulphate, filtered and concentrated under vacuum. The resulting residue was purified 
using silica gel chromatography (2:1 to 1:1 EtOAc: Hexanes) to get 38 (22 mg, 56%) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 4.87 – 4.72 (m, 8H), 4.47 (t, J = 6.2, 6.2 Hz, 1H), 4.38 (t, J = 6.2, 6.2 Hz, 
1H), 3.76 (dd, J = 13.8, 5.8 Hz, 2H), 3.52 (dd, J = 10.2, 8.9 Hz, 1H), 3.44 – 3.41 (m, 6H), 3.40 – 3.38 (m, 
6H), 3.37 – 3.30 (m, 1H), 2.70 – 2.60 (m, 1H), 1.95 (dd, J = 6.0, 3.5 Hz, 1H), 1.91 – 1.80 (m, 1H), 1.74 – 
1.61 (m, 3H), 1.61 – 1.47 (m, 2H), 1.42 – 1.22 (m, 10H). 13C NMR (126 MHz, CDCl3) δ 98.49, 98.09, 
97.63, 97.18, 85.02, 83.72, 80.32, 79.74, 78.99, 61.29, 56.30, 56.17, 55.94, 55.59, 43.45, 42.27, 30.60, 





38 (40 mg, 0.083 mmol) was dissolved in 1 mL of acetonitrile and cooled to 0°C. TMSBr (218 μL, 1.663 
mmol) was added slowly to the mixture and this was stirred for 40 minutes at 0°C. The reaction was 
quenched with 2 mL of saturated sodium bicarbonate while stirring vigorously at 0°C and allowed to 
warm to room temperature. The solvent was removed under vacuum. The resulting solids were dissolved 
in 1:1 MeOH:CHCl3, filtered and the solvents were again removed under vacuum. This crude mixture 
was purified using silica gel column chromatography (14% to 19%, MeOH: CHCl3) and lyophilized to get 
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39 (19 mg, 75%) as an white solid. 1H NMR (500 MHz, CD3OD) δ 4.46 (dd, J = 5.0, 10.9 Hz, 1H), 4.37 
(dd, J = 5.0, 10.9 Hz, 1H), 3.76 – 3.67 (m, 1H), 3.66 – 3.58 (m, 1H), 3.24 (dd, J = 18.7, 9.9 Hz, 1H), 3.06 
(dd, J = 10.1, 10.2 Hz, 1H), 2.45 – 2.29 (m, 1H), 2.24 – 2.10 (m, 1H), 1.99 – 1.90 (m, 1H), 1.77 – 1.51 
(m, 5H), 1.51 – 1.24 (m, 10H). 13C NMR (126 MHz, CD3OD) δ 84.20, 77.85, 74.07, 73.43, 73.12, 62.05, 
45.83, 45.42, 31.66, 30.65, 30.59, 30.55, 30.35, 28.37, 26.32. LRMS (ESI): m/z Calcd for [C15H28FNO4 + 

























The n.c.a. [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction from [18O]H2O on a TR-24 
Cyclotron (Advanced Cyclotron Systems Inc., Richmond, Canada). Cyclotron-produced [18F]fluoride was 
then trapped on a Waters Sep-Pak® light QMA anion-exchange cartridge conditioned with 5 mL of 1M 
K2CO3 followed by 10 mL of H2O. The [
18F]fluoride was eluted with 86% K(2.2.2.)/K2CO3 (1.5 mL) into 
reactor 1 of the GE TRACERlab™ FX automated synthesis module. This solution was then dried 
azeotropically with additional acetonitrile (2 x 1 mL) under vacuum under a steady stream of nitrogen at 
70°C and 120°C. Once fully dried, (4-iodophenyl)diphenylsulfonium triflate (10mg, 0.0186 mmol) in 
acetonitrile (1mL) was added and reacted for 15 min at 90 °C. Once the reaction was completed, the 
mixture was diluted with water (12mL) and passed through a Waters Sep-Pak® tC18 plus light cartridge. 
The cartridge was washed with additional water (10mL), and [18F]FIB was eluted off in acetonitrile (1 
mL) into reactor 2 which already contained 35 (3.15 mg, 0.0131 mmol), 0.5 mg of Pd(PPh3)4, 0.5 mg of 
CuI and 100 μL of TEA in 1 mL of H2O. This reactor was heated to 90°C for 20 minutes. The mixture 
was cooled, filtered through a Nylon 0.2 μm filter then purified using HPLC and analyzed using radio-
TLC. 
 




(±)- (1R,2S,3R,4R,5S,6S)-7-(9-[F18-fluorononyl)-7-azabicyclo[4.1.0]heptane-2,3,4,5-tetraol (43) 
The n.c.a. [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction from [18O]H2O on a TR-24 
Cyclotron (Advanced Cyclotron Systems Inc., Richmond, Canada). Cyclotron-produced [18F]fluoride was 
then trapped on a Waters Sep-Pak® light QMA anion-exchange cartridge conditioned with 5 mL of 1M 
K2CO3 followed by 10 mL of H2O. The cartridge was rinsed with 5 mL of hexanes to remove the excess 
water then elute backwards using 15 mg of TEAB in 1 mL of pure acetonitrile into a 2 mL Eppendorf 
tube containing 37 (8 mg, 0.014 mmol) in 0.25 mL of acetonitrile. This solution was heated at 90°C on a 
thermomixer for 15 minutes then cooled to room temperature. Once the mixture was cooled 0.25 mL of a 
1.15 M solution of TMSBr was added and the reaction was mixed for an additional 20 minutes. At this 
time 0.5 mL of saturate NaHCO3 was added to quench the reaction. Radio-TLC showed the first reaction 
was successful but the second was not. 
Enzyme Kinetic Experiments 
Inactivation solutions contained a final concentration of 16.55 nM of Cerezyme® (Recombinant 
GCase) in 200 μL of Reaction Buffer (50 mM acetate, 0.2 % v/v Triton X-100, 0.3 % w/v sodium 
taurocholate, pH 5.5). The Cerezyme® was collected from left over patient vials and shown by Adams et 
al. to be approximately 8275 nM in the vial. These enzyme Reaction Buffers were brought to 37°C and 
spiked with a corresponding inhibitor to make the final inhibitor concentration either 20 nM, 40 nM, 60 
nM, 80 nM, 120 nM, 160 nM and 200 nM. Once the inhibitor was added this was considered time = 0 
minutes. Meanwhile a 96 well plate inside a Biotek Synergy 4 hybrid multi-mode reader at 37°C is being 
incubated. In the wells of the plate are waiting a high concentration of 2,4-DNP-β-Glc substrate what 
concentration? in 180 μL of Reaction Buffer. As the inhibitor inactivation is occurring, 20 μL aliquots are 
taken from the inactivation solutions and diluted on the plate containing the substrate bringing the final 
concentration of the substrate to 4 mM. Once all the aliquots are added the wells measured for absorbance 
at 400 nm for 8 minutes. At this time the measurements are paused and the next set of aliquots are taken 
to see how residual enzyme activity changes over time. Inactivation rates for varying inhibitor 
concentrations are calculated using GraphPad Prism software and Equation 1. These observed rate 
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Appendix  1a: 1H NMR in CDCl3 of Compound isolated from cold reaction of 40 with KF, K222, K2CO3 in 
ACN at 90°C for 15 minutes 
 
Appendix  1b: 1H NMR in CDCl3 of Compound isolated from cold reaction of 40 with KF, K222, K 2CO3 in 
ACN at 90°C for 15 minutes 
 
